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Abstract
The hepatic transcription factor forkhead box O1 (FOXO1) is a critical regulator of hepatic and systemic
insulin sensitivity. Previous studies demonstrate that genetic inhibition of liver FOXO1 improves insulin
sensitivity in both genetic and dietary mouse models of metabolic disease. Mechanistically, this is due in
part to cell non-autonomous control of adipose tissue insulin sensitivity. However, the mechanisms
mediating this liver-adipose tissue crosstalk remain ill-defined. This thesis work comprises of two studies
that sought to determine the role of hepatic insulin signaling via FOXO1 regulation over adipose tissue
biology. The brown adipose tissue’s (BAT) ability to increase energy expenditure has made it a potential
target for combating obesity, diabetes, and associated diseases. However, significant gaps remain in our
understanding of how metabolic organs, such as the liver, coordinate the supply of hepatokines and
energy substrates that can activate and fuel BAT thermogenesis. In the first study, we identify a role for
hepatic insulin signaling via AKT-FOXO1 in the adaptive response to acute cold stress. Mechanistically,
inhibition of FOXO1 by AKT controls BAT thermogenesis by enhancing catecholamine-induced lipolysis in
the white adipose tissue and increasing circulating fibroblast growth factor 21 (FGF21). These studies
provide relevant and missing fundamental knowledge to the liver’s response to acute cold exposure, in
addition to providing an understanding of the inter-organ communication system that mobilizes energy
for heat production. In the second study, we investigated how the FOXO1-dependent hepatokine FGF21
regulates glucose homeostasis, insulin tolerance and adipocyte lipolysis. The pharmacological effect of
FGF21 on metabolism has been fairly well-studied, however how hepatic insulin signaling contributes to
the regulation of endogenous hepatic FGF21 expression and its physiological role as a FOXO1-dependent
hepatokine in the regulation of metabolism is not completely understood. We demonstrated that acute
deletion of FGF21 did not alter glucose tolerance, insulin tolerance, or adipocyte lipolysis suggesting a
permissive role for endogenous FGF21 and that liver FOXO1 controls glucose homeostasis independently
of liver-derived FGF21. Taken together, these two studies have developed a deeper understanding on the
cell-autonomous and cell-nonautonomous regulation of liver hepatic insulin signaling via FOXO1.
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ABSTRACT

ELUCIDATING THE ROLE OF HEPATIC FOXO1 SIGNALING IN THE REGULATION OF
ADIPOSE TISSUE BIOLOGY
Jaimarie Sostre Colón
Paul M. Titchenell, PhD

The hepatic transcription factor forkhead box O1 (FOXO1) is a critical regulator
of hepatic and systemic insulin sensitivity. Previous studies demonstrate that genetic
inhibition of liver FOXO1 improves insulin sensitivity in both genetic and dietary mouse
models of metabolic disease. Mechanistically, this is due in part to cell non-autonomous
control of adipose tissue insulin sensitivity. However, the mechanisms mediating this
liver-adipose tissue crosstalk remain ill-defined. This thesis work comprises of two
studies that sought to determine the role of hepatic insulin signaling via FOXO1
regulation over adipose tissue biology. The brown adipose tissue’s (BAT) ability to
increase energy expenditure has made it a potential target for combating obesity,
diabetes, and associated diseases. However, significant gaps remain in our
understanding of how metabolic organs, such as the liver, coordinate the supply of
hepatokines and energy substrates that can activate and fuel BAT thermogenesis. In the
first study, we identify a role for hepatic insulin signaling via AKT-FOXO1 in the adaptive
response to acute cold stress. Mechanistically, inhibition of FOXO1 by AKT controls BAT
thermogenesis by enhancing catecholamine-induced lipolysis in the white adipose tissue
and increasing circulating fibroblast growth factor 21 (FGF21). These studies provide
relevant and missing fundamental knowledge to the liver’s response to acute cold
exposure, in addition to providing an understanding of the inter-organ communication
system that mobilizes energy for heat production. In the second study, we investigated
iv

how the FOXO1-dependent hepatokine FGF21 regulates glucose homeostasis, insulin
tolerance and adipocyte lipolysis. The pharmacological effect of FGF21 on metabolism
has been fairly well-studied, however how hepatic insulin signaling contributes to the
regulation of endogenous hepatic FGF21 expression and its physiological role as a
FOXO1-dependent hepatokine in the regulation of metabolism is not completely
understood. We demonstrated that acute deletion of FGF21 did not alter glucose
tolerance, insulin tolerance, or adipocyte lipolysis suggesting a permissive role for
endogenous FGF21 and that liver FOXO1 controls glucose homeostasis independently
of liver-derived FGF21. Taken together, these two studies have developed a deeper
understanding on the cell-autonomous and cell-nonautonomous regulation of liver
hepatic insulin signaling via FOXO1.
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CHAPTER 1: Introduction
The rise in obesity, as well as type 2 diabetes mellitus (T2DM), has become a
nationwide epidemic increasing the number of associated diseases such as kidney
failure and cardiovascular diseases. Therefore, the need to discover new therapeutic
targets to ameliorate these metabolic diseases is necessary. Obesity is caused by a
dysregulation in energy balance, and the liver, via insulin signaling, is an important
regulator of systemic nutrient homeostasis. It coordinates metabolism through insulindependent activation of the serine/threonine-protein kinase B, also known as AKT. Upon
insulin stimulation, AKT is activated in a phosphoinositide 3-kinase (PI3K)-dependent
manner (Manning & Toker, 2017).
One of the key downstream targets of AKT is the family of forkhead box O
(FOXO) transcription factors. In mammals, there are four isoforms of the FOXO
transcription factors family (FOXO1, FOXO3a, FOXO4, and FOXO6); of these, FOXO1
is the primary FOXO isoform in the liver. The AKT-dependent inhibition of FOXO1 is
central to the control of hepatic lipid synthesis, glucose production, and insulin sensitivity
(Titchenell et al., 2017). This is due in part to the hepatic FOXO1-dependent cellnonautonomous control of adipose tissue insulin sensitivity (Perry et al., 2015; Tao et al.,
2018; Titchenell et al., 2016). However, the mechanisms mediating this liver-adipose
tissue crosstalk remain ill-defined. This thesis work comprises of two studies that sought
to determine the role of hepatic insulin signaling via FOXO1 regulation over adipose
tissue biology.
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REGULATION OF FORKHEAD BOX O
Hormone regulation
Insulin and glucagon are the most important pancreatic-derived hormones for
metabolic organs such as the liver. Insulin is synthesized and secreted by pancreatic βcells and is the key hormone for the regulation of glucose and lipid homeostasis. Insulin
action stimulates glucose uptake into adipocytes and skeletal muscle cells. It also
controls blood glucose levels by suppressing hepatic gluconeogenesis through
regulation of transcription factors.
One key insulin-regulated transcription factor is Forkhead Box O1 (FOXO1),
which under fasted conditions or when insulin levels are low activates genes that encode
key gluconeogenic enzymes. Insulin signaling inhibits FOXO1 activity through
posttranslational modifications, namely phosphorylation at Thr24, Ser253, and Ser316
by AKT and subsequent nuclear exclusion. Insulin also stimulates acetylation of FOXO1
by p300 (Perrot and Rechler, 2005), however this results in only modest suppression of
FOXO1-dependent transcription, suggesting that AKT-mediated phosphorylation of
FOXO1 is the predominant mechanism by which insulin inhibits FOXO1.
AKT is a critical node in the hepatic insulin signaling cascade. In mammals, there
are three isoforms of AKT (AKT1, AKT2, and AKT3). AKT1 and AKT2 are the dominant
isoforms in insulin-responsive metabolic tissues such as muscle, adipose tissue, and
liver, while AKT3 is mostly expressed in the brain and testes (Walker et al., 1998; Cho et
al., 2001; Easton et al., 2005; Lu et al., 2012; Koren et al., 2015; Jaiswal et al., 2019). In
vivo studies in mice have demonstrated that the primary phenotypes caused by loss of
liver AKT signaling are driven by sustained FOXO1-mediated transcription (Titchenell et
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al., 2016). Thus, FOXO1 is the key downstream target of AKT signaling for many
physiological processes.
During fasting conditions, pancreatic -cells synthesize and secrete glucagon to
increase circulating glucose. Glucagon binds to the glucagon receptor whereby adenylyl
cyclase is activated, increasing intracellular cyclic adenosine monophosphate (cAMP) to
subsequently activate protein kinase A (PKA) (Ali and Drucker, 2009; Edgerton and
Cherrington,

2011). Glucagon-dependent

cAMP-PKA

activation regulates

gene

expression for glycogenolysis and gluconeogenesis, such as Pygl, G6pc, and Pck1
(Mayr and Montminy, 2001). This cascade also regulates FOXO1 activity by promoting
nuclear translocation and stability via cAMP/PKA–dependent phosphorylation of FOXO1
at Ser276 in human hepatocytes and Ser273 in mice (Wu et al., 2018). Glucagon
signaling has been shown to induce FOXO1 phosphorylation via p38 MAPK signaling
(Ozcan et al., 2012), potentially at the previously described p38 phosphorylation sites
Ser284, Ser295, Ser326, Ser467 and Ser475 (Asada et al., 2007).
Regulation via Post-transcriptional modifications
FOXO activity is highly regulated by several post-transcriptional modifications
(PTMs). Phosphorylation, acetylation, lysine/arginine methylation, O-GlcNAcylation and
ubiquitination have all been described to regulate FOXO proteins. However, regulation
via phosphorylation and acetylation are the most understood.
Phosphorylation
Without insulin stimulation, or during starvation, FOXO1 is dephosphorylated and
translocates to the nucleus to regulate gene transcription (Biggs Iii et al., 1999).
However, in response to insulin or growth factors, activation of AKT directly
phosphorylates

three

conserved

FOXO1
3

residues

(T24,

S256,

and

S319).

Phosphorylation of two of these sites (T24 and S256) allows binding of the 14-3-3 family
of phospho-binding proteins, which induces an acute translocation of FOXO proteins
from the nucleus into the cytoplasm, thus inhibiting the FOXO1 transcriptional program
(Brunet et al., 1999; Kops et al., 1999) (Figure 1.1). Mutation of these phosphorylation
sites to alanine generates a constitutively active FOXO1 mutant that does not respond to
AKT activation, thus decreasing its translocation to the cytoplasm. Mouse models with
hepatic mutation of these sites demonstrate the key role of AKT-dependent regulation of
FOXO1 in systemic metabolism (Zhang et al., 2006).
FOXO proteins are phosphorylated by kinases in addition to AKT. Wu et al,
showed that glucagon regulates FOXO1 by promoting nuclear translocation and stability
via cAMP- and protein kinase A–dependent phosphorylation of FOXO1 at Ser276. This
group performed knock-in studies in mice where Foxo1-S273 was replaced with alanine
(A) or aspartate (D) to block or mimic phosphorylation, respectively, and these mice
displayed impaired blood glucose homeostasis (Wu et al., 2018). Under conditions of
oxidative stress, c-Jun N-terminal kinase (JNK) or macrophage-stimulating 1 (Mst1) can
phosphorylate FOXO proteins leading to FOXO translocation to the nucleus (Lin, 2003;
Essers et al., 2004; Sunayama et al., 2005; Lehtinen et al., 2006; Carter and Brunet,
2007; Yuan et al., 2009; Eijkelenboom and Burgering, 2013; Weng et al., 2016; Calissi,
Lam and Link, 2021). AMP-activated protein kinase (AMPK) (Carter and Brunet, 2007;
Eijkelenboom and Burgering, 2013; Zou et al., 2016; Calissi, Lam and Link, 2021), ERK
(Carter and Brunet, 2007; Eijkelenboom and Burgering, 2013; Mezza et al., 2016;
Calissi, Lam and Link, 2021) and p38 MAPK can also phosphorylate and regulate FOXO
proteins (Carter and Brunet, 2007; Eijkelenboom and Burgering, 2013; Calissi, Lam and
Link, 2021). Thus, FOXO phosphorylation is controlled by several proteins, with AKT4

dependent phosphorylation being the most understood, and is a key post-transcriptional
modification that regulates FOXO activity.

Figure 1. 1 Schematic regulation of insulin-dependent AKT-mediated inhibition of FOXO

Acetylation
FOXO proteins are also regulated by acetylation or deacetylation on lysine
residues. FOXO1 is known to be acetylated at (Lys 219, Lys 242, Lys 245, Lys 259, Lys
262, Lys 271, and Lys 291) (Brunet et al., 2004; van der Heide and Smidt, 2005; Qiang,
Banks and Accili, 2010; Pramanik et al., 2014). Acetylation can occur via the histone
acetyltransferase, cAMP-response element-binding protein (CREB)-binding protein
(CBP) or p300, decreasing the DNA-binding ability of FOXO1 and hence reducing its
activity (Daitoku et al., 2004; Matsuzaki et al., 2005; Perrot and Rechler, 2005).
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Deacetylation occurs via the NAD-dependent histone deacetylase silent information
regulator 2 (Sir2) and this increases the DNA-binding activity of FOXO.
The Accili group developed two mouse models to study FOXO1 acetylation: one
with a constitutively acetylated FOXO1 and the second with a constitutively deacetylated
FOXO1. They showed that constitutively acetylated FOXO1 predominantly localizes to
the cytoplasm, consistent with inactivation of FOXO1 activity. In contrast, a constitutively
deacetylated form of FOXO1 is predominantly localized in the nucleus with increased
FOXO1 activity. These mice with deacetylated FOXO1 were hyperglycemic and insulinresistant, which is attributed to increased FOXO1 activity (Banks et al., 2011).
ROLE OF LIVER FORKHEAD BOX O IN GLUCOSE HOMEOSTASIS
Systemic homeostasis is imperative for proper function of the human body. The
liver is critical in maintaining systemic homeostasis. One of its key functions is the
regulation of glucose and lipid metabolism. Glucose homeostasis is maintained by
regulation of glucose production in the liver and glucose disposal in the skeletal muscle
and adipose tissue (Lange et al., 2007).
In states of low nutrient availability or during fasting, the liver initially increases
systemic glucose supply initially via glycogenolysis, or the breakdown of liver glycogen
content, and then, during prolonged fasting via gluconeogenesis, or the de novo
production of glucose (Postic, Dentin and Girard, 2004). This de novo glucose production
involves the use of non-carbohydrate precursors such as glycerol, lactate, and amino
acids to make glucose (Gross, van den Heuvel and Birnbaum, 2008). Three key
enzymes involved in the regulation of gluconeogenesis are G6Pase, fructose-1,6biphosphatase and PEPCK (Altomonte et al., 2003; Lin and Accili, 2011; Titchenell et al.,
6

2016). G6Pase promotes the dephosphorylation of glucose-6-phosphate, allowing the
release of the newly synthesized glucose into the bloodstream, while PEPCK is the rate
limiting enzyme that phosphorylates oxaloacetate to form phosphoenolpyruvate. FOXO1
interacts with the peroxisome proliferator-activated receptor gamma coactivator 1-alpha
(PGC1α) to induce the expression of Pepck and G6pc (Yoon et al., 2001). On the other
hand, postprandial nutrient availability leads to insulin secretion from the pancreas and
subsequent activation of hepatic insulin signaling. In the liver, insulin signaling activates
AKT and this leads to the inhibition of both glycogenolysis and gluconeogenesis through
multiple downstream pathways including glycogen synthase kinase 3 (GSK3) and
FOXO1 (Cross et al., 1995).
Over the years, genetic manipulation (loss or gain of function) of mainly the
FOXO1 isoform or a combination of isoforms (FOXO1, FOXO3A, FOXO4) has
demonstrated the role of the FOXO proteins in glucose metabolism and insulin
sensitivity. In 2006, the Unterman group demonstrated that chronic liver expression of an
active FOXO1 isoform leads to increased plasma insulin and glucose levels (Zhang et
al., 2006). Consistent with this, our group recently showed that acute liver expression of
an active FOXO1 isoform is sufficient to increase fasting insulin levels and decrease
glucose tolerance (Sostre-Colón et al., 2021). Conversely, the Accili group developed a
liver specific FOXO1 knockout mouse and showed that these mice have reduced
glucose levels due to decreased hepatic glucose production (Matsumoto et al., 2007).
Consistent with the idea that reduction of hepatic FOXO1 is a potent insulin sensitizer,
deletion of hepatic FOXO1 is sufficient to improve glucose tolerance and fasting insulin
levels in mice under obesogenic diets. Although FOXO1 is known to be the most active
isoform in the liver, Haeusler et al, demonstrated that ablation of all three FOXO proteins
7

(FOXO1, FOXO3A, FOXO4) in the liver causes greater effects on glucose metabolism,
when compared to the single FOXO1 liver knockout mice (Haeusler, Kaestner and Accili,
2010; Haeusler et al., 2014).
Further evidence that hepatic FOXO affects glucose and insulin sensitivity was
shown in mice with systemic insulin resistance and glucose intolerance due to lack of
liver insulin receptor (IR), insulin receptor substrate 1/2 (IRS1/2), or AKT1/2. Under
these conditions, concomitant loss of hepatic FOXO1 function is sufficient to rescue
glucose tolerance and insulin sensitivity, suggesting that increased activity of FOXO1 in
the liver mediates both of these phenotypes. These FOXO1-dependent effects on
glucose tolerance and insulin sensitivity are attributed to cell-nonautonomous control
over adipose tissue (Perry et al., 2015; Tao et al., 2018a; Stöhr et al., 2021).
Forkhead box O 1 cell-nonautonomous regulation of white adipose tissue lipolysis
Mammals have evolved the advantage of storing nutrients for later use during
prolonged fasting. White adipose tissue (WAT) stores excess energy in the form of
triglycerides. The main function of WAT is to maintain lipid homeostasis in response to
insulin and nutritional status. Insulin plays a major effect on systemic metabolism by
suppressing lipid breakdown and fatty acid release from adipose tissue. Upon feeding,
insulin promotes energy storage in WAT and suppresses triglyceride hydrolysis
(lipolysis) to protect other organs such as the muscle and liver from the harmful effects
of lipid overload. This maintains systemic insulin responsiveness given that high plasma
and cellular FA concentrations have been associated with increased insulin resistance
(Titchenell et al., 2016).
During starvation, energy demands increase and so does lipolysis to meet this
demand. The sympathetic nerve response plays a major role in promoting lipolysis via
8

the secretion of the catecholamine and β-adrenergic agonist norepinephrine (NE) in
adipose tissue (Lafontan et al., 1997). NE triggers a cAMP/PKA-dependent signaling
cascade leading to the phosphorylation of perilipin 1 and hormone sensitive lipase (HSL)
and, stimulating a three-step lipolytic response (Villena et al., 2004; Zimmermann et al.,
2004; Egan et al., 2006; Duncan R.E., Ahmadian M, Jaworski K, Sarkadi-Nagy E, 2010).
The first step involves the phosphorylation of perilipin 1 in the lipid droplet by PKA
leading to the release of comparative gene identification-58 (CGI-58). In turn, CGI-58
associates with and activates adipose triglyceride lipase (ATGL), which is the first
enzyme in the lipolytic cascade, responsible for hydrolyzing triglycerides into
diglycerides (Villena et al., 2004; Zimmermann et al., 2004). The second step occurs
when PKA phosphorylates HSL, causing HSL to translocate from the cytosol to the
surface of the lipid droplet where it hydrolyzes diglycerides into monoglycerides (Egan et
al., 2006). Finally, the last enzyme in the lipolysis cascade, monoglyceride lipase (MGL),
hydrolyzes monoglycerides to form free fatty acids and glycerol. This results in the
release of three non-esterified free fatty acids (NEFA) and a molecule of glycerol into
circulation for peripheral tissue consumption (Duncan R.E., Ahmadian M, Jaworski K,
Sarkadi-Nagy E, 2010). As mentioned before, insulin is known to attenuate this lipolytic
response.

The

antilipolytic

effect

of

insulin

is

attributed

to

activation

of

phosphodiesterase 3B (PDE3B), which induces cAMP hydrolysis (Young et al., 2006).
The reduction of cAMP levels in adipocytes decreases PKA-dependent signaling, which
causes lipolytic signaling to return to its basal state.
Titchenell et al, using the hyperinsulinemic euglycemic clamp technique,
demonstrated that loss of hepatic FOXO1 in mice lacking AKT1/2 in the liver reduces
hepatic glucose production (HGP) by enhancing the insulin-dependent inhibition of
9

lipolysis in the WAT, leading to less NEFA’s fueling HGP (Titchenell et al., 2016). Morris
White’s group using mice lacking hepatic IRS1/2 arrived at the same conclusion,
however, they identified the FOXO1-dependent hepatokine follistatin as the factor
responsible for decreased insulin sensitivity in the adipose tissue of mice with increased
FOXO1 activity (Tao et al., 2018b).
Forkhead box O 1-dependent control of fibroblast growth factor 21
One hepatokine that has been thought to also play a role in this liver-adipose
tissue crosstalk is the hepatokine fibroblast growth factor 21 (FGF21), which also is
known to affect carbohydrate and lipid metabolism (BonDurant and Potthoff, 2018).
Circulating FGF21 is mainly derived from the liver (Markan et al., 2014) and signals
through the cell-surface FGF receptor 1c (FGFR1c) isoform and its co-receptor β-klotho,
a single-pass transmembrane protein (Ogawa et al., 2007; Kharitonenkov et al., 2008;
Suzuki et al., 2008; Ding et al., 2012). FGF21 activation of the FGFR1c/β-klotho complex
leads to several signaling events, including regulation of peripheral metabolism by the
central nervous system (Owen et al., 2014). Several physiological challenges induce
FGF21 expression, including nutrient restriction caused by fasting or low protein diets
(Inagaki et al., 2007; Laeger et al., 2014; Maida et al., 2016), and carbohydrate intake of
glucose, sucrose, and fructose (Dushay et al., 2015; Talukdar et al., 2016; von HolsteinRathlou et al., 2016; Iroz et al., 2017; Lundsgaard et al., 2017). Our group and others
used genetically engineered mouse models to demonstrate that Fgf21 gene expression
is increased with genetic ablation of hepatic FOXO1 (Haeusler, Han and Accili, 2010;
Ling et al., 2017; Sostre-Colón et al., 2021; Stöhr et al., 2021). These data suggest that
hepatic insulin signaling via FOXO1 is an essential regulator of hepatic FGF21
expression.
10

Two studies have addressed the role of hepatic FOXO1 in regulating liverderived FGF21 and its consequent effects on systemic metabolism. Stöhr et al. showed
that FGF21 overexpression in congenital IRS1/2 and FOXO1 knockouts increases
adipose tissue glucose uptake, which correlated with systemic insulin sensitivity changes
(Stöhr et al., 2021). However, recent studies by our lab did not observe any changes in
glucose tolerance, insulin tolerance, adipose tissue insulin sensitivity, or lipolysis
following acute knockout of hepatic AKT1/2, FOXO1 and FGF21 (Sostre-Colón et al.,
2022). This suggests a permissive role for FOXO1-dependent regulation of liver FGF21
in the regulation of systemic glucose homeostasis and insulin tolerance in mice.
Forkhead box O 1-dependent control of stress-induced hyperglycemia
FOXO has also been shown to control systemic metabolism during stressinduced hyperglycemia through cell-autonomous and nonautonomous mechanisms.
Stress-induced hyperglycemia caused by trauma, sepsis, stroke, and others, is
associated with poor outcomes in nearly all critical illnesses. It is often attributed to
insulin resistance because controlling glucose levels via exogenous insulin infusion
improves survival (Li and Messina, 2009). Our group recently demonstrated that stressinduced hyperglycemia is associated with reduced hepatic insulin signaling and
increased hepatic FOXO target gene expression, such as G6pc. Loss of FOXO1,
FOXO3, and FOXO4 in the liver attenuate hyperglycemia and prevent hyperinsulinemia.
Mechanistically, loss of liver FOXO1, FOXO3 and FOXO4 isoforms mitigates the stressinduced hyperglycemia response by directly altering gluconeogenic gene expression and
glycogenolysis in the liver and indirectly suppressing lipolysis in adipose tissue (Garcia
Whitlock et al., 2021).

11

ROLE OF LIVER FORKHEAD BOX O IN LIPID METABOLISM
In addition to its role in glucose homeostasis, FOXO is a key transcription factor
regulating lipid metabolism. Liver-specific transgenic expression of active FOXO1
induces expression of genes involved in lipid transport. However, transcription of
lipogenic genes does not appropriately increase postprandially, leading to a reduction in
lipogenesis. On the other hand, mice with deletion of all FOXO proteins from the liver
exhibit increased lipogenic gene expression and de novo lipogenesis. Although FOXO1
is canonically shown to be a transcriptional activator, the specific mechanism governing
its transcriptional inhibition of lipogenesis is unclear. Nevertheless, studies demonstrated
that FOXO1 directly represses the transcription of sterol response element-binding
protein-1c (SREBP1c) (Deng et al., 2012). SREBP1c is a member of the SREBP class
of transcription factors that are key players in controlling cellular expression of genes
required for lipid and cholesterol metabolism (Deng et al., 2012). FOXO1 not only
inhibits SREBP-1c but also suppresses the expression of genes directly involved in fatty
acid synthesis, including fatty acid synthase and ATP citrate lyase (Zhang et al., 2006).
FOXO1 has also been implicated in regulating the expression of glucokinase
(GCK) (Langlet et al., 2017). GCK catalyzes the phosphorylation of glucose to glucose6-phosphate (Zhang et al., 2006). Increased hepatic GCK expression is associated with
lipogenesis and fatty liver in humans. Regulation of GCK expression depends on
insulin/AKT-dependent signaling, and deletion of FOXO1 partially increases GCK
expression in mice lacking hepatic AKT, however, additional activation of mTORC1 is
required for full activation of GCK (Titchenell et al., 2016). Moreover, SIN3 transcription
regulator family member A (SIN3A) was identified as an insulin sensitive FOXO1
corepressor of GCK (Langlet et al., 2017). SIN3A knockout interferes with GCK
expression regulated by FOXO1 in response to environmental nutrients, while not
12

affecting expression of other genes targeted by FOXO1, such as G6pc (Langlet et al.,
2017).
Another component of lipid metabolism is the secretion of liver triglycerides into
the plasma. A portion of newly synthesized triglycerides are stored in the liver, but under
normal conditions, most are packaged along with other proteins and lipids into very lowdensity lipoprotein particles (VLDL). Liver FOXO1 has been shown to affect lipid
metabolism through regulation of VLDL secretion in addition to its regulation of SREBP1c and GCK. However, studies on the role of FOXO1 in triglyceride secretion have
yielded conflicting results. Altomonte et al, reported that chronic hepatic expression of an
active form of FOXO1 increased apolipoprotein C-III (ApoCIII) and circulating VLDL
particles. They went on to show that FOXO1 is necessary and sufficient to increase
expression of the microsomal TG transfer protein, which further promotes hepatic VLDL
triglyceride production (Altomonte et al., 2004; Kamagate et al., 2008). However, Zhang
et al, observed that FOXO1 decreased serum triglyceride levels due to reduced VLDL
triglyceride content and failed to reproduce the induction of ApoCIII in vivo and in vitro
(Zhang et al., 2006). Consistent with the latter, hepatic deletion of FOXO1 does not alter
serum triglyceride levels, and ablating FOXO1 in mice lacking IRS1/2 or AKT1/2 in the
liver partially restores the deficit in VLDL triglyceride secretion (Titchenell et al., 2016;
Tao et al., 2018a).
ROLE OF LIVER FORKHEAD BOX O IN ACUTE COLD EXPOSURE
In addition to the cell-autonomous control of hepatic FOXO1 previously stated,
FOXO1 signaling in the liver is an important systemic regulator of thermogenesis.
Organismal stressors such as cold exposure require a systemic response to maintain
body temperature. Brown adipose tissue (BAT) is a key thermogenic tissue in mammals
13

that protects against hypothermia in response to cold exposure. BAT uses multiple
substrates, such as lipids and glucose, to convert chemical energy to heat via the highly
enriched mitochondrial uncoupling protein 1 (UCP1). UCP1 resides within the
mitochondrial inner membrane of brown adipocytes and, when activated, dissipates the
proton gradient, resulting in increased electron transport chain activity and heat
production (Jacobssons et al., 1985). Upon cold exposure, the sympathetic nervous
system (SNS) triggers the release of the catecholamine norepinephrine (NE)
(Klingenspor, 2003; Bartness, Vaughan and Song, 2010). NE acts on β-adrenergic
receptors (β-AR) which cause an elevation of cAMP and PKA-activity to coordinate
glucose and lipid uptake, lipolysis, and an increase in the resting energy expenditure
through non-shivering thermogenesis in brown adipocytes (Jacobssons et al., 1985)
(Figure 1.2). NE is also known to induce lipolysis in WAT through β-AR (Lafontan et al.,
1997). This increase in WAT lipolysis is required to fuel non-shivering thermogenesis
upon fasting conditions (Schreiber et al., 2017) (Figure 1.2). Additionally, WAT lipolysis
causes an increase in insulin that is needed for lipid uptake into the thermogenically
activated BAT (Heine et al., 2018). This increase in WAT lipolysis upon cold exposure
also causes an increase in circulating non-esterified fatty acids (NEFA) which can be
taken up by the liver. Furthermore, previous data suggest that upon cold exposure, the
liver takes up long chain fatty acids (FA) released from WAT and converts them into
acylcarnitine to be used as fuel for brown fat thermogenesis (Simcox et al., 2017).
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Figure 1. 2: β-adrenergic receptor signaling pathways of adipocyte thermogenic program

Two recent studies demonstrated that increased hepatic FOXO1 activity caused
by deletion of hepatic IRS1/2 or AKT1/2 leads to cold sensitivity (Sostre-Colón et al.,
2021; Stöhr et al., 2021). Mechanistically, Störh et al suggest that this cold response
regulation by FOXO1 is due to its regulation of FGF21 and its role in increasing SNS and
Ucp1 gene expression (Stöhr et al., 2021), while our lab argues that liver FOXO1
orchestrates this response to acute cold exposure through two independent
mechanisms: (1) by its regulation of FGF21 and (2) by cell-nonautonomous regulation of
WAT lipolysis (Sostre-Colón et al., 2021).
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ABSTRACT

Organismal stressors such as cold exposure require a systemic response to maintain
body temperature. The brown adipose tissue (BAT) is a key thermogenic tissue in
mammals that protects against hypothermia in response to cold exposure. Defining the
complex interplay of multiple organ systems in this response is fundamental to our
understanding of adipose tissue thermogenesis. Here, we identify a role for hepatic
insulin signaling via AKT in the adaptive response to cold stress and show that liver AKT
is an essential cell-nonautonomous regulator of adipocyte lipolysis and BAT function.
Mechanistically, inhibition of FOXO1 by AKT controls BAT thermogenesis by enhancing
catecholamine-induced lipolysis in the white adipose tissue (WAT) and increasing
circulating FGF21. Our data identify a role for hepatic insulin signaling via the AKTFOXO1 axis in regulating WAT lipolysis, promoting BAT thermogenic capacity, and
ensuring a proper thermogenic response to acute cold exposure.
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INTRODUCTION
The ability to maintain body temperature is essential for mammalian survival.
Upon an organismal stressor such as cold exposure, mammals increase heat production
by both shivering and non-shivering thermogenesis, where the brown adipose tissue
(BAT) serves as the major site for cold-induced non-shivering thermogenesis (Cannon
and Nedergaard, 2004a). BAT uses multiple substrates to convert chemical energy to
heat via the highly enriched mitochondrial uncoupling protein 1 (UCP1) – a hallmark of
brown adipocytes. UCP1 resides within the mitochondrial inner membrane of brown
adipocytes, and when activated, UCP1 dissipates the proton gradient generated,
increased electron transport chain activity and heat production (Jacobssons et al., 1985).
Upon cold exposure, the sympathetic nervous system (SNS) triggers the release
of the catecholamine norepinephrine (NE), which acts on β-adrenergic receptors on
adipocytes to stimulate the production of cyclic adenosine monophosphate (cAMP) and
activation of protein kinase A (PKA) (Tj, Ch and Ck, 2010; Morrison, Madden and
Tupone, 2012). Once activated, PKA coordinates a host of metabolic actions, including
glucose and lipid uptake in BAT to promote non-shivering thermogenesis (Smith and
Horwitz, 1969; Himms-Hagen, 1976; Cannon and Nedergaard, 2004b; Heine et al.,
2018a). Moreover, PKA signaling induces lipolysis in the white adipose tissue (WAT) by
stimulating the cAMP/PKA-dependent phosphorylation of hormone-sensitive lipase
(HSL) and perilipin (Egan et al., 2006; Zechner et al., 2012). Even though cold exposure
increases intra-BAT lipolysis (Cannon and Nedergaard, 2004b), this process is not
required for the thermogenic response. Rather, WAT lipolysis is necessary to provide
free fatty acids (FFA) to fuel the thermogenic response upon cold exposure when
exogenous nutrients are limiting (Schreiber et al., 2017a; Shin et al., 2017a).
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In addition to the cell-autonomous control of adipocyte function and activity, the liver is
an important systemic regulator of carbohydrate and lipid homeostasis. Central to liver
metabolic function is the insulin-dependent activation of protein kinase B, also known as
AKT. Three AKT isoforms exist in mammalian systems (AKT1, AKT2, and AKT3);
however, AKT1 and AKT2 are the dominant functional isoforms in insulin-responsive
metabolic tissues such as muscle, adipose tissue, and liver, while AKT3 is mainly
expressed in the brain and testis (Walker et al., 1998; Cho et al., 2001; Easton et al.,
2005; Lu et al., 2012; Shearin et al., 2016; Jaiswal et al., 2019). Upon insulin stimulation,
AKT is activated in a phosphoinositide 3-kinase (PI3K)-dependent manner (Burgering
and Coffer, 1995; Manning and Toker, 2017). One of the major downstream targets of
AKT are the family of forkhead box O (FOXO) transcription factors, in which
phosphorylation by AKT causes acute translocation of FOXO proteins from the nucleus
into the cytoplasm thus inhibiting the FOXO transcriptional program (Brunet et al., 1999;
Kops et al., 1999). This AKT-dependent inhibition of FOXO is central to the control of
hepatic lipid synthesis and glucose production (Titchenell, Lazar and Birnbaum, 2017).
Moreover, insulin inactivation of FOXO1, the main isoform of the FOXO family in the
liver, is necessary for cell-nonautonomous control of hepatic glucose production via
enhancing insulin sensitivity in the white adipose tissue (O-Sullivan et al., 2015; Perry et
al., 2015; Titchenell et al., 2015, 2016a; Tao et al., 2018).
In addition to cell intrinsic signaling mechanisms, hepatokines, in particular,
fibroblast growth factor 21 (FGF21), are important regulators of peripheral metabolism
(BonDurant and Potthoff, 2018). FGF21 signals through the cell-surface FGF receptor 1c
(FGFR1c) isoform and its co-receptor β-klotho, a single-pass transmembrane protein
(Ogawa et al., 2007a; Kharitonenkov et al., 2008; Suzuki et al., 2008; Ding et al., 2012).
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FGF21 activation of the FGFR1c/β-klotho complex leads to several signaling events
including the phosphorylation of FGFR substrate 2α and phosphorylation of the Raf-1
and extracellular signal-regulated kinases (ERK1/2) (Kharitonenkov et al., 2005; Ogawa
et al., 2007b). In rodents, cold exposure induces Fgf21 gene expression in BAT, inguinal
white adipose tissue (iWAT) and liver, while in humans, cold exposure increases
circulating FGF21 levels (Lee et al., 2013; Huang et al., 2017; Ameka et al., 2019;
Hollstein et al., 2020). Recent studies suggest that hepatic FGF21 also stimulates BAT
activity via central brain action, which in turn increases sympathetic nerve activity (SNA)
in BAT (Chartoumpekis et al., 2011; Hondares et al., 2011; Fisher et al., 2012; Ameka et
al., 2019).
Recent work demonstrates that during acute cold exposure, FFAs are liberated
from the WAT and lead to the generation of liver-derived acylcarnitines and triglyceriderich lipoproteins that are important stimulators of the BAT thermogenic response
(Simcox et al., 2017a; Heine et al., 2018b). However, significant gaps remain in our
understanding of how the generation of these circulating substrates are coordinated and
to what extent the liver is involved in orchestrating this response. New evidence
indicates that insulin levels rise during acute cold exposure (Heine et al., 2018b) leading
us to hypothesize that hepatic insulin action is an important integrator of the systemic
response to cold. In this manuscript, we uncover a role for hepatic insulin signaling via
the AKT-FOXO1 axis in regulating WAT lipolysis, maintaining BAT thermogenic
capacity, and ensuring a proper thermogenic response to prolonged fasting and acute
cold exposure.
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RESULTS
Hepatic AKT regulates BAT thermogenic capacity
Insulin rises 2-fold and is required for the thermogenic response to acute cold
exposure (Heine et al., 2018b). Given that hepatic insulin signaling is central to the
systemic effects of insulin, we assessed liver insulin signaling by measuring AKT
activation in response to acute cold exposure in mice. Phosphorylation of AKT at
Ser473/474 was significantly increased within 30 minutes of cold exposure (Figure
2.1A). In addition, a single injection of CL-316,243 (CL) (1 mg/kg), a selective β3adrenergic receptor agonist known to pharmacologically mimic cold exposure (Bloom et
al., 1992; Cannon and Nedergaard, 2004b), stimulated robust AKT phosphorylation in
liver (Figure 2.1A). Notably, this activation of AKT led to a functional increase in AKT
signaling as shown by increased phosphorylation of the downstream marker, ribosomal
protein S6 at Ser240/244 (Figure 2.1A).
To evaluate the physiological significance of hepatic AKT stimulation, we
generated an inducible knockout of both AKT isoforms (L-AktDKO) in the adult liver.
Here, we injected 6-14 week old adult Akt1loxp/loxp; Akt2loxp/loxp mice with an adenoassociated virus expressing Cre recombinase under the control of the thyroxine-binding
globulin (Tbg) promoter for liver specificity (AAV8-TBG-CRE) to generate L-AktDKO
mice (Lu et al., 2012). Floxed littermates were injected with AAV8-TBG-GFP and served
as control mice (Control). All experiments were performed two weeks post-injection to
mitigate any potential compensatory mechanisms. We confirmed liver-specific knockout
by measuring protein levels of AKT1 and AKT2 in primary hepatocytes as well as in
whole liver tissue (Figure 2.1B). Residual of AKT1 protein was observed in liver tissue
from L-AktDKO mice; however, primary hepatocytes isolated from L-AktDKO displayed
negligible amounts of both AKT1 and AKT2 protein, indicating that residual AKT1
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expression is due to non-hepatocyte cells present in tissue liver lysates (Lu et al., 2012;
Titchenell et al., 2016a). As expected, both AKT1 and AKT2 protein levels were
unaffected in BAT of L-AktDKO mice, confirming the liver selective effect of the AAV8TBG approach (Figure 2.1B). Furthermore, recent data using single-cell RNAseq of
mice injected with AAV8-CRE to induce knockout has further validated this viral
approach for inducible and hepatocyte-specific knockouts in mice (Guan et al., 2020).
Due to the role of BAT in thermogenesis and cold tolerance, we first assessed
how loss of liver AKT signaling affected BAT morphology and activity. BAT harvested
from ad libitum fed L-AktDKO mice at room temperature (RT) was paler (data not
shown) and showed a dramatic increase in lipid droplet deposition (Figure 2.1C), which
correlated with increased expression of genes involved in fatty acid synthesis (Figure
2.2A-C). To assess the physiological relevance of these changes in BAT, we performed
an acute cold tolerance test (CTT), which consisted of moving mice from RT to 4°C for
up to 5 hours without food. L-AktDKO mice failed to increase Ucp1 and Dio2 gene
expression upon an acute CTT (Figure 2.1D). This expression correlated with a
significant decrease in UCP1 protein levels in the BAT of cold-exposed L-AktDKO mice
(Figure 2.1E). To determine if these changes in BAT morphology and UCP1 levels
affected the thermogenic capacity of L-AktDKO mice, we used metabolic cages to
measure oxygen consumption (VO2) upon NE injection (1 mg/kg). Control mice
increased VO2 ~2-fold and this response was markedly blunted in L-AktDKO mice
(Figure 2.1F). Lastly, L-AktDKO mice displayed a dramatic increase in cold sensitivity,
losing body temperature rapidly, as compared to Control mice following acute cold
exposure (Figure 2.1G).
Previous studies have documented significant systemic and adipose tissue insulin
resistance in L-AktDKO mice (Lu et al., 2012; Titchenell et al., 2016b). Therefore, we
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next determined if these changes in the BAT of L-AktDKO mice are driven by insulin
resistance in fat tissue. To directly assess the contribution of adipose tissue insulin
signaling, we generated mice lacking Akt2 specifically in fat cells (F-AKT2KO) and
subjected these mice to the same cold-induced thermogenic challenges. Similar to other
models of reduced adipose tissue insulin signaling (Tang et al., 2016), these mice failed
to increase insulin signaling in epididymal white adipose tissue (eWAT) following insulin
stimulation (Figure 2.3A). However, neither cold sensitivity or UCP1 protein levels were
affected in F-AKT2KO mice, demonstrating that reduced insulin signaling in fat cells per
se is not sufficient to alter the thermogenic response, BAT lipid content or adipose tissue
lipolysis during cold challenge (Figure 2.3B-F). Overall, these data demonstrate that
hepatic AKT signaling regulates the BAT thermogenic response and maximal
thermogenic capacity, independent of AKT signaling directly in fat cells.
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Figure 2. 1: The loss of liver AKT reduces BAT thermogenic capacity
A) Western Blot analysis of p-AKT (Ser473/474), p-Akt (Ser474) and p-S6 (Ser240/244) of liver
from Control mice housed at RT or 4°C for 30 minutes or 60 minutes and before and after 30
minutes of CL i.p. injection. B) Western Blot analysis of AKT1, AKT2 and IGFBP1 from primary
hepatocytes and liver, and AKT1, and AKT2 of BAT from Control and L-AktDKO mice two weeks
post-AAV8 injection housed at RT. C) Hematoxylin and eosin staining of BAT from Control and
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L-AktDKO mice housed at RT or 4°C for 3 h (Scale Bar=100 µm). D) Relative mRNA levels of
Ucp1 and Dio2 in BAT from Control and L-AktDKO mice housed at RT or 4°C for 3 h (n=6-10
mice per group). E) Western Blot analysis of UCP1 of BAT from Control and L-AktDKO mice
housed at RT or 4°C for 3 h. F) Rate of oxygen consumption (VO2) of Control and L-AktDKO
mice housed at 25°C after 1 mg/kg Norepinephrine i.p. injection (n=6 for Control mice and n=5 for
L-AktDKO mice). G) Core body temperature of Control and L-AktDKO mice during a fasting acute
cold tolerance test for 3h (RT→4°C) (n=8 for Control mice and n=9 for L-AktDKO mice). Data are
presented as means ±SEM. *p<0.05, **p<0.01, ***p<0.001.

Figure 2. 2: The loss of liver AKT increases BAT fatty acids synthesis genes
A-C) Relative mRNA levels of Fasn, Acc and Scd1 in BAT from Control and L-AktDKO mice
housed at RT or 4°C for 3 h (n=3 per group). Data are presented as means ±SEM. *p<0.05,
**p<0.01, ***p<0.001.
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Figure 2. 3: The acute cold thermogenic response is independent of adipocyte AKT2
signaling
A) Western Blot analysis of p-AKT (Ser473/474), p-AKT2 (474), p-PRAS40 (Thr246), and p-S6
(Ser240/244) of eWAT from Control and F-AKT2KO mice under unstimulated or stimulated
conditions with insulin (2 U/kg) for 20 min after overnight fasting. B) Western Blot analysis of
AKT2 and UCP1 of BAT from Control and F-AKT2KO after a fasting cold tolerance test for 5 h. C)
Core body temperature of Control and F-AKT2KO mice during a fasting acute cold tolerance test
for 5 h (RT→4°C) (n=4 per group). D) H&E staining of BAT from Control and F-AKT2KO after a
fasting cold tolerance test for 5 h. (Scale Bar= 200µm). E) Glycerol serum levels of Control and FAKT2KO after a fasting cold tolerance test for 5 h (n=3 for Control, and n=4 for F-AKT2KO mice).
F) NEFA serum levels of Control and F-AKT2KO after a fasting cold tolerance test for 5 h (n=3 for
Control, and n=4 for F-AKT2KO mice). Data are presented as means ±SEM. *p<0.05, **p<0.01,
***p<0.001.
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Hepatic AKT signaling regulates fat mass by increasing food intake
Given the dysfunction of BAT in L-AktDKO mice, we measured the effects on
body mass and body composition. Ad libitum fed L-AktDKO mice two-weeks post AAV8
injection showed a significant increase in total body mass, mainly reflected in increased
fat mass (Figure 2.4A). This increase in fat mass correlated to an ~0.1 g increase in
epididymal (eWAT) and inguinal white adipose tissue (iWAT) mass as well as a ~0.5 g
increase in BAT mass when compared to Control mice (Figure 2.4B). Next, we
determined if the increased body mass of L-AktDKO mice was due to increased energy
consumption or a reduction in energy expenditure. We placed Control and L-AktDKO
mice in metabolic cages to measure the rate of oxygen consumption (VO 2) and the rate
of carbon dioxide production (VCO2). L-AktDKO mice had modestly elevated VO2, VCO2,
and respiratory exchange ratio (RER) during the light cycle consistent with elevated
body mass (Figure 2.4C-E). Next, we measured food intake prior to AAV8 injection and
2-weeks post-injection. Akt1loxp/loxp; Akt2loxp/loxp mice showed no difference in food intake
before AAV8 delivery; however, 2-weeks post-injection L-AktDKO mice displayed a
significant increase in cumulative food intake (Figure 2.4F). Collectively, these data
indicate that inhibition of hepatic AKT increases body weight by increasing food intake,
rather than decreasing energy expenditure.
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Figure 2. 4: Inhibition of hepatic AKT increases fat mass via increased energy intake
A) Body composition of Control and L-AktDKO mice housed at RT (n=5 per group). B) Epididymal
(eWAT), inguinal (iWAT) and brown (BAT) fat pads weight of Control and L-AktDKO mice housed
at RT (n=5-7 per group). C) Rate of oxygen consumption (VO 2) of Control and L-AktDKO mice
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housed at 25°C (n=7 per group). D) Rate of carbon dioxide production (VCO 2) of Control and LAktDKO mice housed at 25°C (n=7 per group). E) Respiratory exchange ratio (RER) of Control
and L-AktDKO mice housed at 25°C (n=7 per group). F) Cumulative food intake of Control and LAktDKO mice housed at RT before and after two weeks post-AAV8 injection (n=6 for Control
mice and n=7 for L-AktDKO mice). Data are presented as means ±SEM. *p<0.05, **p<0.01,
***p<0.001.

Inhibition of hepatic FOXO1 by AKT is required for proper BAT thermogenic capacity
AKT signals through many downstream signaling pathways to regulate systemic
metabolism. In liver, the phosphorylation and inhibition of the forkhead box O (FOXO)
transcriptionfactors are important determinants of glucose and lipid homeostasis
(Titchenell, Lazar and Birnbaum, 2017). FOXO1, the main isoform of the FOXO family in
hepatocytes, is known to be active in insulin-resistant mouse models (Aoyama, Daitoku
and Fukamizu, 2006; Titchenell et al., 2016a). Consistent with previous reports, LAktDKO mice have increased IGFBP1 levels, a direct transcriptional target of FOXO1
(Figure 2.1B). To determine if increased hepatic FOXO1 in L-AktDKO mice was
responsible for the decreased thermogenic response, we injected AAV8-TBG-CRE into
Akt1loxp/loxp; Akt2loxp/loxp; FoxO1loxp/loxp mice to generate L-AktFoxo1TKO (Lu et al., 2012)
and AAV8-TBG-GFP to littermate mice to serve as Controls. Following AAV8-TBG-CRE
injection, AKT1, AKT2 and FOXO1 protein levels were ablated in isolated primary
hepatocytes from L-AktFoxo1TKO mice; however, there was no change in expression of
these proteins in the BAT (Figure 2.5A). Two-weeks post-injection, both Control and LAktFoxo1TKO mice displayed identical body and adipose tissue mass (eWAT and
iWAT), and only a modest increase in BAT mass, which is in stark contrast to the
previously described L-AktDKO mice (Figure 2.5B-C; Figure 2.4B). Unlike L-AktDKO
mice, BAT from L-AktFoxo1TKO mice appeared histologically normal and expressed
normal levels of UCP1 protein at both RT and 4°C (Figure 2.5D-E). Moreover, L37

AktFoxo1TKO mice had a normal increase in the oxygen consumption response upon
NE injection and were able to defend their body temperature during an acute CTT
(Figure 2.5F-G). These data indicate that AKT inhibition of hepatic FOXO1 is required
for regulation of body mass, BAT thermogenic capacity, and acute cold tolerance.
Next, we sought to determine if increased hepatic FOXO1 was sufficient to impair
adipose tissue thermogenesis. We injected Foxo1AAAloxp/loxp mice (Ouyang et al., 2012a)
with AAV8-TBG-CRE/GFP to generate mice with acute, liver-specific activation of
FOXO1 (L-Foxo1AAA) or control (Control) mice, respectively. L-Foxo1AAA mice lack the
AKT-dependent inhibition by having its regulatory phosphorylation sites mutated to
alanine leading to constitutive activity. We confirmed increased liver FOXO1 activity and
specificity by observing only increased liver gene expression and protein levels of
IGFBP1, a direct FOXO1 transcriptional target, and not in BAT (Figure 2.6A-C). Twoweeks post-injection, L-Foxo1AAA mice displayed impaired glucose tolerance and
fasting hyperinsulinemia (Figure 2.6D,E), indicating an insulin-resistant phenotype as
previously described by Terry Unterman’s group using a congenital liver-specific
Foxo1AAA mouse model (Zhang et al., 2006). Consistent with our findings in L-AktDKO
mice, L-Foxo1AAA mice showed impaired cold tolerance and decreased UCP1 protein
levels in BAT (Figure 2.6F,G). This reduction in cold tolerance correlated with a
significant reduction in FFA serum levels (Figure 2.6H), further supporting the important
role for hepatic FOXO1 signaling downstream of AKT in the regulation of thermogenesis.
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Figure 2. 5: The loss of hepatic FOXO1 is sufficient to rescue thermogenic capacity in LAktDKO mice
A) Western Blot analysis of AKT1, AKT2 and FOXO1 from primary hepatocytes and BAT from
Control and L-AktFoxo1TKO mice two weeks post-AAV8 injection housed at RT. B) Body mass
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of Control and L-AktFoxo1TKO mice housed at RT (n=9 for Control mice and n=11 for LAktFoxo1TKO mice). C) Epididymal (eWAT), inguinal (iWAT) and brown (BAT) fat pads weight of
Control and L-AktFoxo1TKO mice housed at RT (n=7 for Control mice and n=8 for LAktFoxo1TKO mice). D) Hematoxylin and eosin staining of BAT from Control and LAktFoxo1TKO mice housed at RT or 4°C for 5 h (Scale Bar=100 µm). E) Western Blot analysis of
UCP1 of BAT from Control and L-AktFoxo1TKO mice housed at RT or 4°C for 5 h. F) Rate of
oxygen consumption (VO2) of Control and L-AktFoxo1TKO mice housed at 25°C after 1 mg/kg
NE i.p. injection (n=4 for Control mice and n=7 for L-AktFoxo1TKO mice). G) Core body
temperature of Control and L-AktFoxo1TKO mice during a fasting acute cold tolerance test for 5 h
(RT→4°C) (n=7 for Control mice and n=9 for L-AktFoxo1TKO mice). Data are presented as
means ±SEM. *p<0.05, **p<0.01, ***p<0.001.
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Figure 2. 6: Hepatic FOXO1 is sufficient to impair cold tolerance
A) Relative mRNA levels of Igfbp1, Gck, Akt2, and Fgf21 in liver from Control and L-Foxo1AAA
mice (n=5 for Control mice and n=6 for L-Foxo1AAA mice). B) Western Blot analysis of IGFBP1
of liver from Control and L-Foxo1AAA mice. C) Relative mRNA levels of Igfbp1, and Gck in BAT
from Control and L-Foxo1AAA mice (n=5 for Control mice and n=6 for L-Foxo1AAA mice). D)
Glucose levels of Control and L-Foxo1AAA mice housed at RT after i.p. injection of 2 mg/kg of
glucose solution (n=3 for Control mice and n=4 for L-Foxo1AAA mice). E) Fasting insulin levels of
Control and L-Foxo1AAA mice housed at RT (n=3 for Control mice and n=4 for L-Foxo1AAA
mice). F) Core body temperature of Control and L-Foxo1AAA mice during a fasting acute cold
tolerance test for 5 h (RT→4°C) (n=5 for Control mice and n=6 for L-Foxo1AAA mice). G)
Western Blot analysis of UCP1 of BAT from Control and L-Foxo1AAA mice after a fasting acute
cold tolerance test for 5 h. H) NEFA serum levels of Control and L-Foxo1AAA mice after a fasting
acute cold tolerance test for 5 h (n=5 for Control mice and n=6 for L-Foxo1AAA mice). Data are
presented as means ±SEM. *p<0.05, **p<0.01, ***p<0.001.
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Liver AKT signaling regulates catecholamine-induced lipolysis
In addition to intrinsic BAT mechanisms, WAT lipolysis is required to maintain
body temperature during cold exposure as mice with adipocyte-specific loss of the
lipolysis regulators adipocyte triglyceride lipase (ATGL) or CGI-58 exhibit profound cold
sensitivity (Schreiber et al., 2017b; Shin et al., 2017b). Given the similarities with the LAktDKO mouse phenotype, we hypothesized that catecholamine-induced lipolysis may
be impaired in L-AktDKO mice. To test this hypothesis, we measured serum FFA and
glycerol levels in response to an intraperitoneal (i.p.) injection of CL (1 mg/kg). LAktDKO mice displayed a blunted rise in FFA levels in response to CL, as compared to
Control and L-AktFoxo1TKO mice (Figure 2.7A). Similar to CL administration, L-AktDKO
mice exposed to an acute CTT showed a significant reduction in serum FFAs when
compared to Control and L-AktFoxo1TKO mice; this correlated with a decrease in
hepatic triglyceride content suggesting reductions in WAT lipolysis and liver fatty acid reesterification (Figure 2.7B-C). Consistent with defective WAT lipolysis in L-AktDKO
mice, phosphorylation of PKA substrates, phosphorylation of HSL at Ser660 and
phosphorylation of Perilipin at Ser522 were decreased in eWAT of L-AktDKO mice
following acute cold exposure (Figure 2.7D-E). Villanueva’s group showed that coldinduced activation of WAT lipolysis is required to increase acylcarnitines for BAT
thermogenesis (Simcox et al., 2017b). Concordant with the impaired lipolysis observed
in L-AktDKO mice, the serum levels of numerous acylcarnitines levels were
downregulated upon acute cold exposure in L-AktDKO mice compared to Control mice
(Figure 2.8A).
Surprisingly, glycerol levels of L-AktDKO mice did not track with changes in
serum FFAs (Figure 2.9A). Since the liver is a large consumer of glycerol and hepatic
insulin signaling is known to be involved in glycerol metabolism, we determined if L42

AktDKO mice have defective glycerol clearance. In support of this notion, L-AktDKO
mice were glycerol intolerant when subjected to glycerol tolerance test (Figure 2.9B),
and this correlated with decreased hepatic gene expression of Gk, Gpd1, and Gpd2
(Figure 2.9C). Therefore, serum glycerol measurements are a poor indicator of adipose
tissue lipolysis in mice lacking hepatic AKT signaling due to abnormalities in glycerol
clearance. Together, these data indicate that loss of hepatic AKT signaling impairs
catecholamine-stimulated lipolysis, an effect that is dependent upon intact liver FOXO1
signaling.
To determine if impaired catecholamine-induced lipolysis in L-AktDKO mice
lowers core body temperature under other physiological conditions such as prolonged
fasting, we starved Control and L-AktDKO mice for 24 hours, and measured core body
temperature and FFAs immediately upon food removal and 24 hours later. L-AktDKO
mice showed a significant decrease of ~0.5°C of core body temperature when compared
to Control mice at baseline and a further decrease of ~1°C after 24 hours of fasting
(Figure 2.7F). The decreased core body temperature tracked with lowered FFA levels
both at 0 and 24 hours of fasting (Figure 2.7G). Together, these data indicate that LAktDKO mice have impaired catecholamine-induced lipolysis that is associated with
reduced core body temperature.
Next, we wanted to address if providing exogenous nutrients would be sufficient
to rescue the cold sensitivity observed in L-AktDKO mice. Therefore, we performed an
acute CTT in which L-AktDKO mice were either fasting for the duration of the experiment
or ad libitum fed. As previously observed in Figure 2.1G, food deprived L-AktDKO mice
were cold sensitive. However, cold tolerance was rescued in ad libitum fed L-AktDKO
mice (Figure 2.7H), suggesting that the cold sensitivity developed by L-AktDKO mice
upon acute cold exposure is associated with depletion of circulating energy substrates.
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This rescue in cold tolerance by food was independent of changes of UCP1 protein
levels (Figure 2.7I). Lastly, we addressed if the impairment in catecholamine-induced
lipolysis observed in WAT of L-AktDKO mice was due to a tissue-autonomous or
nonautonomous mechanism. We performed a lipolysis ex vivo assay in which glycerol
and FFA levels were measured in the media of eWAT explants upon CL treatment.
Explants of eWAT from L-AktDKO mice induced glycerol and FFA levels to a similar
extent as Control mice (Figure 2.7J), suggesting that the impaired catecholamineinduced lipolysis is due to a tissue-extrinsic mechanism.
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Figure 2. 7: L-AktDKO mice fail to respond to catecholamine-induced lipolysis in WAT
A) NEFA serum levels of Control, L-AktDKO, and L-AktFoxo1TKO mice housed at RT before and
after 30 min of CL i.p. injection (n=5-9 per group). B) NEFA serum levels of Control, L-AktDKO,
and L-AktFoxo1TKO mice after a fasting acute cold tolerance test for 5 h (RT→4°C) (n=6-15 per
group). C) Hepatic triglyceride content of Control, L-AktDKO, and L-AktFoxo1TKO mice after a
fasting acute cold tolerance test for 5 h (RT→4°C) (n=7-20 per group). D) Western Blot analysis
of p-PKA substrate of eWAT from Control and L-AktDKO mice after a fasting acute cold tolerance
test for 5 h (RT→4°C). E) Western Blot analysis of p-HSL (Ser660), and p-Perilipin (Ser522) of
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eWAT from Control and L-AktDKO mice after a fasting acute cold tolerance test for 5 h
(RT→4°C). F) Core body temperature of Control and L-AktDKO mice housed at RT before and 24
h after fasting (n=11 for Control mice and n=8 for L-AktDKO mice). G) NEFA serum levels of
Control and L-AktDKO mice housed at RT before and 24 h after fasting (n=6 for Control mice and
n=5 for L-AktDKO mice). H) Core body temperature of Control and L-AktDKO mice during a
fasting acute cold tolerance and L-AktDKO mice during ad-libitum fed acute cold tolerance test for
5 h (RT→4°C) (n=8 for Control mice and n=7 for L-AktDKO mice per condition). I) Western Blot
analysis of UCP1 of BAT from Control and L-AktDKO mice after a fasting acute cold tolerance
and L-AktDKO mice after ad-libitum fed acute cold tolerance test for 5 h. J) Glycerol and NEFA
serum levels of Control and L-AktDKO mice eWAT fat pads before and after 100 µM CL
treatment (n=3 for Control mice and n=4 for L-AktDKO mice). Data are presented as means
±SEM. *p<0.05, **p<0.01, ***p<0.001.

Figure 2. 8: The inhibition of liver AKT decreases serum acylcarnitines levels
A) Acylcarnitines serum levels of Control and L-AktDKO mice after a fasting acute cold tolerance
test for 5 h (n=3 per group). Data are presented as means ±SEM. *p<0.05, **p<0.01, ***p<0.001.
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Figure 2. 9: The loss of hepatic AKT impairs glycerol metabolism
A) Glycerol serum levels of Control and L-AktDKO mice housed at RT before and after 30 min of
CL 316,243 i.p. injection (n=6 for Control mice and n=7 for L-AktDKO mice). B) Glycerol serum
levels of Control and L-AktDKO mice housed at RT after i.p. injection of 2 mg/kg glycerol solution
(n=3 per group). C) Relative mRNA levels of Gk, Gpd1 and Gpd2 in liver from Control and LAktDKO mice after a fasting cold tolerance test for 5 h (n=6 for Control mice and n=5 for LAktDKO mice). Data are presented as means ±SEM. *p<0.05, **p<0.01, ***p<0.001.
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Induction of FGF21 by hepatic insulin signaling plays a key role in acute cold sensitivity
Collectively, our data show that hepatic AKT-FOXO1 axis regulates BAT
thermogenic capacity and catecholamine-stimulated lipolysis. Therefore, we focused on
candidate hepatokines that may be involved in thermoregulation as well as lipolysis.
Endogenous FGF21 increases upon acute cold exposure (Lee et al., 2013; Ameka et al.,
2019) and signals to the central nervous system to regulate core body temperature
(Ameka et al., 2019). Previous work suggests that FGF21 expression and secretion are
regulation by AKT (Izumiya et al., 2008), and combined with our data, indicating a
potential link between hepatic AKT-FOXO1 signaling and FGF21 production to regulate
adipose tissue thermogenesis and lipolysis. Consistent with this notion, L-AktDKO mice
showed a significant reduction in liver Fgf21 gene expression compared to Control and
L-AktFoxo1TKO mice at RT (Figure 2.10A). Moreover, L-AktDKO mice failed to
stimulate Fgf21 gene expression in response to acute cold exposure (Figure 2.10A).
This reduction in Fgf21 gene expression correlated to a ~75% reduction in FGF21 serum
levels in L-AktDKO mice (Figure 2.10B). Strikingly, both hepatic gene expression and
circulating levels of FGF21 were normal in L-AktFoxo1TKO mice (Figure 2.10A,B).
Additionally, L-AktDKO mice trended to have decreased Fgf21 gene expression in WAT
and BAT when compared to Control mice; however, it did not reach statistically
significance (Figure 2.11A-C), indicating that the main effect of hepatic insulin signaling
is on liver-derived FGF21.
Due to the discrepancy between the pharmacological and physiological role of
FGF21 in both thermogenesis and lipolysis, we focused on the physiological role of
FGF21

and

determined

if

hepatic

AKT-FOXO1

controls

thermogenesis

and

catecholamine-induced lipolysis via liver-derived FGF21. To address this question, we
employed a genetic approach and crossed Akt1loxp/loxp; Akt2loxp/loxp; FoxO1loxp/loxp mice with
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Fgf21loxp/loxp mice to generate Akt1loxp/loxp; Akt2loxp/loxp; FoxO1loxp/loxp; Fgf21loxp/loxp mice.
These mice were injected with AAV8-TBG-CRE to generate mice lacking AKT1, AKT2,
FOXO1, and FGF21 in the liver (L-AktFoxo1Fgf21QKO) and floxed littermates were
injected with AAV8-TBG-GFP to serve as control mice (Control) (Figure 2.10C,D). First,
we addressed the thermogenic capacity of L-AktFoxo1Fgf21QKO mice by measuring
VO2 in response to NE injection. L-AktFoxo1Fgf21QKO mice displayed a significant
reduction in VO2 upon NE compared to Control mice, suggesting an impairment in BAT
thermogenic capacity (Figure 2.10E).

When subjected to an acute CTT, L-

AktFoxo1Fgf21QKO mice displayed mildly impaired cold tolerance compared to Control
mice (Figure 2.10F). This cold sensitivity did not correlate with decreased UCP1 protein
levels in BAT (Figure 2.10G), but is consistent with previous work demonstrating that
FGF21 regulates BAT thermogenesis through sympathetic nerve activity (Ameka et al.,
2019). NEFA serum levels and hepatic triglyceride content of L-AktFoxo1Fgf21QKO
mice were significantly increased compared to Control mice despite cold intolerance
(Figure 2.10H,I). Notably, the increase in hepatic TAG levels in L-AktFoxo1Fgf21QKO
mice could also be attributed to FOXO1 inhibition, as L-AktFoxo1TKO mice have
increased levels of liver TAG during cold exposure without increased FFAs as compared
to Control mice (Figure 2.7B,C). Nevertheless, these results align with studies indicating
an inhibitory role for FGF21 on lipolysis (Arner et al., 2008; Li et al., 2009; Geng et al.,
2019) but indicates that a FGF21-independent mechanism must exist for liver AKT to
regulate adipocyte lipolysis cell-nonautonomously. Collectively, our data show that
hepatic liver insulin signaling regulates thermogenesis during thermal challenge, via
FGF21-upregulation of BAT activity and by a FGF21-independent signal that controls
adipocyte lipolysis. This demonstrates an essential role for the hepatic insulin-AKTFOXO1 axis in the control of mammalian thermogenesis.
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Figure 2. 10: Hepatic AKT-FOXO1 regulates liver-derived FGF21 and plays a key role in
cold sensitivity
A) Relative mRNA levels of Fgf21 in liver from Control, L-AktDKO and L-AktFoxo1TKO mice
house at RT or after a fasting acute cold tolerance test for 5 h (RT→4°C) (n=5-14 per group). B)
FGF21 serum levels of Control, L-AktDKO and L-AktFoxo1TKO mice after a fasting acute cold
tolerance test for 5 h (RT→4°C) (n=9 per group). C) Relative mRNA levels of Akt2, Foxo1, and
Fgf21 in liver from Control, and L-AktFoxo1Fgf21QKO mice after a fasting acute cold tolerance
test for 5 h (RT→4°C) (n=6 for Control mice and n=7 for L-AktFoxo1Fgf21QKO mice). D) FGF21
serum levels of Control, and L-AktFoxo1Fgf21QKO mice after a fasting acute cold tolerance test
for 5 h (RT→4°C) (n=6 for Control mice and n=7 for L-AktFoxo1Fgf21QKO mice). E) Rate of
oxygen consumption (VO2) of Control and L-AktFoxo1Fgf21QKO mice housed at 25°C after 1
mg/kg NE i.p. injection (n=7 for Control mice and n=6 for L-AktFoxo1Fgf21QKO mice). F) Core
body temperature of Control and L-AktFoxo1Fgf21QKO mice during a fasting acute cold
tolerance test for 5 h (RT→4°C) (n=8 per group). G) Western Blot analysis of UCP1 of BAT from
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Control and L-AktFoxo1Fgf21QKO mice after a fasting acute cold tolerance test for 5 h
(RT→4°C). H) NEFA serum levels of Control and L-AktFoxo1Fgf21QKO mice after a fasting
acute cold tolerance test for 5 h (RT→4°C) (n=7 for Control mice and n=8 for LAktFoxo1Fgf21QKO mice). I) Hepatic triglyceride content of Control and L-AktFoxo1Fgf21QKO
mice after a fasting acute cold tolerance test for 5 h (RT→4°C) (n=7 for Control mice and n=9 for
L-AktFoxo1Fgf21QKO mice). Data are presented as means ±SEM. *p<0.05, **p<0.01,
***p<0.001.
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Figure 2. 11: Fgf21 and β-Klotho gene expression in BAT and WAT
A-C) Relative mRNA levels of Fgf21, and Klb from BAT, iWAT and eWAT of Control, L-AktDKO
and L-AktFoxo1TKO mice housed at RT or 4°C for 5 h (n=5-17 per group). Data are presented as
means ±SEM. *p<0.05, **p<0.01, ***p<0.001.
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DISCUSSION
The BAT confers an evolutionary advantage to mammals by playing an important
and well-established role in non-shivering thermogenesis (Cannon and Nedergaard,
2004b). While BAT was long thought to be present exclusively in infants, recent work
revealed that it is also present in adults (Cypess et al., 2009; Lee et al., 2010). Human
studies show that BAT thermogenesis after cold training is associated with increased
oxidative capacity, insulin sensitivity, and decreased body fat mass (Yoneshiro et al.,
2013; Blondin et al., 2014; Lee et al., 2014). The ability of the BAT to increase energy
expenditure has made it a potential target to combat obesity and associated diseases
(Seale and Lazar, 2009). However, major gaps remain in our understanding of BAT
regulation, including how other metabolic organs, such as the liver, coordinate the
supply of hepatokines and energy substrates to activate and fuel BAT thermogenesis.
Elucidating these mechanisms will provide relevant and missing fundamental knowledge
to the liver’s response to acute cold exposure, in addition to providing an understanding
of the inter-tissue communication system that mobilize energy for heat production.
In this study, we tested the direct role of hepatic insulin signaling via AKT in the
regulation of adipose tissue biology during acute cold exposure. Consistent with
increased insulin levels upon acute cold exposure (Heine et al., 2018c), our data reveal
that liver AKT signaling is activated by cold and intact insulin signaling in liver is required
for adipose tissue thermogenesis. Here, we show a role for liver AKT-FOXO1 signaling
in coordinating the response to cold exposure by two independent mechanisms: by
regulating availability of energy substrates from the WAT and by producing the
hepatokine FGF21 to enhance BAT function.
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In response to cold exposure, the BAT uses different substrates to convert
chemical energy to heat (Heine et al., 2018c). Recent studies have challenged the
popular belief that lipolysis and lipid droplets in brown adipocytes are required for BAT
thermogenesis. There is increasing evidence that WAT lipolysis is required to fuel nonshivering thermogenesis during fasting conditions (Schreiber et al., 2017a; Shin et al.,
2017a; Chitraju et al., 2020). Consistent with this notion, our data indicate that liver AKTFOXO1 signaling is required for proper catecholamine-induced lipolysis and defense of
body temperature during an acute cold challenge. This cell-nonautonomous regulation of
liver insulin signaling on WAT is consistent with FOXO1-dependent regulation on WAT
previously reported (Perry et al., 2015; Titchenell et al., 2016a; Tao et al., 2018). Given
the robust regulation of FGF21 gene expression by liver AKT-FOXO1 signaling, we
hypothesized that liver-derived FGF21 was a key hepatokine involved in this response.
Significant controversy exists regarding the role of FGF21 in lipolysis, with some studies
suggesting a lipolysis-promoting effect (Inagaki et al., 2007; Badman et al., 2009), while
other studies indicating an inhibitory role (Arner et al., 2008; Li et al., 2009; Geng et al.,
2019).
To address this directly, we generated a liver-specific knockout of AKT1/2,
FOXO1 and FGF21 to examine if FOXO1 regulation of liver FGF21 directly affects WAT
lipolysis. Surprisingly, our data showed that loss of FGF21 increases WAT lipolysis, as
measured by circulating FFA levels in response to a cold challenge. These results are in
agreement with an inhibitory role of liver FGF21 on WAT lipolysis and suggest FGF21independent mechanisms mediate the improvements of the catecholamine response
following deletion of FOXO1 in L-AktDKO mice. Another possible explanation for the
impaired catecholamine response observed in L-AktDKO mice is decreased expression
54

of β-adrenergic receptors. However, lipolysis stimulation ex vivo or gene expression of
β-adrenergic receptors from BAT and WAT from Control, L-AktDKO and L-AktFoxo1TKO
showed no significant changes indicating a defect in receptor expression does not
underly this effect (Figure 2.7J; Figure 2.12A-C). In addition, it is also plausible that
reduced UCP1 expression per se in L-AktDKO mice can negatively affect the
catecholamine response and adaptive thermogenesis (Matthias et al., 2000). Lastly,
work by Saltiel and others have observed catecholamine resistance and decreased WAT
lipolysis in obesity, caused by WAT inflammation and activation of phosphodiesterase
3B (PDE3B) by the protein kinases IKKε and TBK1 (Mowers et al., 2013). Consistent
with this observation, we observed an increase in IL-1β gene expression, a known proinflammatory cytokine in the WAT of L-AktDKO mice suggesting inflammation may be
contribute to the anti-lipolysis effects (Figure 2.13A). Nevertheless, future studies will
address the direct mechanism of how liver AKT-FOXO1 signaling regulates adipose
tissue metabolic flexibility including its regulation of catecholamine-induced lipolysis and
UCP1 expression.
In addition to lipolysis, the physiologic role of endogenous FGF21 in controlling
thermogenesis is debated. Two important studies have directly evaluated the role of
liver-derived FGF21 in thermoregulation (Huang et al., 2017; Ameka et al., 2019). In
both studies the same mouse model (strain and age) were used; however, different
conclusions are reported. Huang et al., argue that loss of FGF21 in the liver did not have
an effect on thermoregulation. In contrast, Ameka et al., demonstrated that loss of liver
FGF21 affects thermoregulation following acute short-term cold exposure. In our study,
we sought to determine the role of endogenous FGF21 in thermoregulation downstream
of hepatic insulin action. We performed loss of function experiments that indicated
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FOXO1 is an important regulator of FGF21 expression, and this is required for proper
cold tolerance and BAT thermogenic capacity. However, these effects were independent
of changes in UCP1 and WAT lipolysis suggesting additional FGF21-independent
mechanisms must exist to mediate the control of WAT lipolysis by liver AKT-FOXO1
signaling. These data support the work of Ameka et al. that liver derived FGF21 plays a
role in the acute cold response and BAT sympathetic nerve activity, rather than directly
affecting UCP1 expression and generation of circulating nutrients. In addition, our data
support the concept that liver FGF21, the main contributor of circulating FGF21 (Markan
et al., 2014), is under the direct control of hepatic insulin signaling via a AKT-FOXO1dependent mechanism. This insulin control of FGF21 expression is consistent with
humans studies as well as in other mouse models with genetic deletion of hepatic
FOXO1 (Haeusler, Han and Accili, 2010; Ling et al., 2017; Samms et al., 2017).
In summary, maintaining core body temperature during cold exposure is
essential for survival in mammals and requires proper inter-organ communication. In
recent years, a series of seminal reports have begun to delineate the mechanisms of
how this inter-organ communication is critical for the acute response to cold challenge
(Schreiber et al., 2017a; Shin et al., 2017a; Simcox et al., 2017a; Heine et al., 2018c;
Ameka et al., 2019). In this study, we showed a role for hepatic insulin action in
response to acute cold exposure and the cell-nonautonomous regulation of adaptive
thermogenesis. Mechanistically, we show that liver insulin signaling via AKT-FOXO1
axis orchestrates the systemic thermogenic response to acute cold by regulating
catecholamine-induced lipolysis in the WAT and inducing BAT thermogenesis response
via FGF21-dependent and independent mechanisms.
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Figure 2. 12: β-Adrenergic receptors gene expression in BAT and WAT
A-C) Relative mRNA levels of Adrb1, Adrb2, and Adrb3 from BAT, iWAT and eWAT of Control, LAktDKO and L-AktFoxo1TKO mice housed at RT or 4°C for 5 h (n=5-17 per group). Data are
presented as means ±SEM. *p<0.05, **p<0.01, ***p<0.001.
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Figure 2. 13: The inhibition of hepatic AKT increases IL-1β cytokine levels in WAT
A) Relative mRNA levels of IL-1β, Mcp1, Tnfα, and F4/80 in eWAT from Control, L-AktDKO and
L-AktFoxo1TKO mice after a fasting acute cold tolerance test for 5 h (RT→4°C) (n=13 for Control
mice and n=6 for L-AktDKO mice and n=5 for L-AktFoxo1TKO mice). Data are presented as
means ±SEM. *p<0.05, **p<0.01, ***p<0.001.
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CHAPTER 3: Acute deletion of the FOXO1-dependent hepatokine FGF21 does not
alter basal glucose homeostasis or lipolysis in mice
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ABSTRACT
The hepatic transcription factor forkhead box O1 (FOXO1) is a critical regulator of
hepatic and systemic insulin sensitivity. Previous work by our group and others
demonstrate that genetic inhibition of FOXO1 improves insulin sensitivity in both genetic
and dietary mouse models of metabolic disease. Mechanistically, this is due in part to
cell non-autonomous control of adipose tissue insulin sensitivity. However, the
mechanisms mediating this liver-adipose tissue crosstalk remain ill-defined. One
candidate hepatokine controlled by hepatic FOXO1 is fibroblast growth factor 21
(FGF21). Pre-clinical and clinical studies have explored the potential of pharmacological
FGF21 as an anti-obesity and anti-diabetic therapy. In this manuscript, we performed
acute loss-of-function experiments to determine the role of hepatocyte-derived FGF21 in
glucose homeostasis and insulin tolerance in both control and mice lacking hepatic
insulin signaling. Surprisingly, acute deletion of FGF21 did not alter glucose tolerance,
insulin tolerance or adipocyte lipolysis in either liver-specific FGF21KO mice or mice
lacking hepatic AKT-FOXO1-FGF21 suggesting a permissive role for endogenous
FGF21 in the regulation of systemic glucose homeostasis and insulin tolerance in mice.
Additionally, these data indicate that liver FOXO1 controls glucose homeostasis
independently of liver-derived FGF21.
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INTRODUCTION

The liver is an important metabolic organ that orchestrates systemic
carbohydrate and lipid metabolism. One of the liver’s major roles is to respond to periods
of nutrient abundance and scarcity to control systemic metabolism. For example, during
periods of starvation, the liver produces glucose to meet the body’s metabolic demands
by increasing hepatic glucose production. On the other hand, postprandial nutrient
availability leads to insulin secretion from the pancreas and subsequent activation of
hepatic insulin signaling. In the liver, insulin signaling suppresses glucose production by
inhibition of glycogenolysis and gluconeogenesis. In addition to glucose metabolism,
insulin increases de novo lipogenesis, export triglyceride (TG) rich lipoproteins in the
liver, and suppresses fatty acid oxidation (Alan R. Saltiel and C. Ronald Kahn, 2001).
However, in metabolic diseases such as type 2 diabetes mellitus (T2DM) and obesity,
insulin-dependent regulation of these processes is abnormal, leading to sustained
hyperglycemia and lipid synthesis in the face of hyperinsulinemia and insulin resistance
(Rizza, 2010; Lin and Accili, 2011). Thus, understanding the specific mechanisms
underlying hepatic insulin action and the control of systemic glucose and lipid
metabolism is of paramount importance.
The serine/threonine-protein kinase B, also known as AKT, is a critical node in
the hepatic insulin cascade signaling. In mammals, there are three isoforms of AKT
(AKT1, AKT2, and AKT3). AKT1 and AKT2 are the dominant isoforms in insulinresponsive metabolic tissues such as muscle, adipose tissue, and liver (Walker et al.,
1998; Cho et al., 2001; Easton et al., 2005; Lu et al., 2012; Shearin et al., 2016; Jaiswal
et al., 2019). One of the key targets of AKT is the family of forkhead box O (FOXO)
transcription factors. There are multiple isoforms of the FOXO transcription factors family
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in mammals, including FOXO1, FOXO3a, FOXO4, and FOXO6, with FOXO1 serving as
the primary FOXO isoform in the liver. These transcription factors are critical regulators
of several genes involved in the adaptation to fasting and reduced insulin levels (van der
Vos and Coffer, 2011; Webb and Brunet, 2014). In response to insulin action on
hepatocytes, AKT directly phosphorylates three conserved residues (FOXO1: T24,
S256, and S319). Phosphorylation of two of these sites (FOXO1: T24 and S256) allows
the binding of the 14-3-3 family of phospho-binding proteins, which induces an acute
translocation of FOXO proteins from the nucleus into the cytoplasm, thus inhibiting the
FOXO transcriptional program (Brunet et al., 1999; Kops et al., 1999).
The AKT-dependent inhibition of FOXO1 is central to the control of hepatic lipid
synthesis and glucose production (Titchenell, Lazar and Birnbaum, 2017). Loss of
hepatic AKT results in impaired glucose tolerance and systemic insulin resistance;
however, concomitant hepatic deletion of FOXO1 normalizes these metabolic
disturbances. This is due, in part, to the FOXO1-dependent cell-nonautonomous control
of hepatic glucose production via inhibition of white adipose tissue (WAT) lipolysis (Perry
et al., 2015; Titchenell et al., 2016; Tao et al., 2018). Mechanistically, several potential
candidates have been proposed to link excess hepatic FOXO1 activity with adipose
tissue insulin resistance and systemic glucose intolerance (Perry et al., 2015; Tao et al.,
2018; Stöhr et al., 2021).
The hepatokine fibroblast growth factor 21 (FGF21) is implicated in the control of
carbohydrate and lipid metabolism (BonDurant and Potthoff, 2018). Circulating FGF21
levels are mainly derived from the liver (Markan et al., 2014) and signal through the cellsurface FGF receptor 1c (FGFR1c) isoform and its co-receptor β-klotho, a single-pass
transmembrane protein (Ogawa et al., 2007; Kharitonenkov et al., 2008; Suzuki et al.,
2008; Ding et al., 2012). FGF21 activation of the FGFR1c/β-klotho complex leads to
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several signaling events, including regulation of peripheral metabolism via central effects
in the central nervous system (Owen et al., 2014). FGF21 levels increase in response to
several physiological challenges, including nutrient restriction such as fasting, low
protein diets (Inagaki et al., 2007; Laeger et al., 2014; Maida et al., 2016), as well by
carbohydrate intake, including glucose, sucrose, and fructose consumption (Dushay et
al., 2015; Talukdar, Owen, et al., 2016; Von Holstein-Rathlou et al., 2016; Iroz et al.,
2017; Lundsgaard et al., 2017). Recently, work by our group and others demonstrated
that Fgf21 gene expression is increased following genetic deletion of hepatic FOXO1
(Haeusler, Han and Accili, 2010; Ling et al., 2017; Sostre-Colón et al., 2021; Stöhr et al.,
2021), consistent with the insulin-dependent upregulation of FGF21 observed in humans
(Samms et al., 2017). These data suggest that hepatic insulin signaling via FOXO1 is an
essential regulator of hepatic FGF21 expression.
Over the last several years, FGF21 has emerged as a potential treatment for
obesity and T2DM due to the insulin-sensitizing effects seen in obese and insulinresistant mice and non-human primates (Kharitonenkov et al., 2005, 2007; Coskun et al.,
2008; Xu, Lloyd, et al., 2009; Gaich et al., 2013). Even though the metabolic effects of
pharmacological FGF21 administration have been fairly well-studied, gaps remain in our
understanding of how hepatic insulin signaling contributes to the regulation of
endogenous hepatic FGF21 expression and its physiological role as a FOXO1dependent hepatokine in the regulation of metabolism. Relatively limited studies have
addressed the role of liver-derived FGF21 in systemic metabolism; however, these
studies employed chronic models of FGF21 deficiency from birth that may lead to
secondary effects due to sustained FGF21 deficiency (Markan et al., 2014; Stöhr et al.,
2021). Therefore, we evaluated the effects of acute deletion of hepatocyte-specific
FGF21 on glucose homeostasis in control and mice lacking hepatic AKT-FOXO1
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signaling. Interestingly, acute deletion of FGF21 does not alter glucose homeostasis,
insulin tolerance or adipocyte insulin sensitivity in either control or mice lacking hepatic
AKT and FOXO1 signaling, suggesting a minimal role for endogenous FGF21 in the
systemic control of basal glucose homeostasis and adipocyte lipolysis in mice.
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RESULTS
Hepatic AKT-FOXO1 axis regulates glucose tolerance, fasting hyperinsulinemia and
Fgf21 expression
Liver insulin signaling orchestrates systemic metabolism. In mice, deletion of
both liver isoforms of AKT, Akt1 and Akt2, induced insulin resistance and glucose
intolerance, in part by causing adipose tissue insulin resistance. These abnormalities are
dependent on increased FOXO1 activity, as deletion of Foxo1 in the same liver restored
insulin sensitivity and glucose homeostasis via both direct and indirect mechanisms (Lu
et al., 2012). The direct mechanism in liver is likely due to increased expression of
hepatic glucokinase and suppression of G6pc, which restores hepatic glucose utilization.
However, controversy remains over how FOXO1 cell-nonautonomously regulates
adipose tissue insulin sensitivity. To gain more mechanistic insight into the underlying
extra-hepatic mechanisms mediating this effect, we generated new cohorts of mice by
injecting 8 to 14 weeks old Akt1loxP/loxP, Akt2loxP/loxP mice with an adeno associated virus
expressing Cre recombinase or GFP under the thyroxine-binding globulin (Tbg)
promoter to make an acute liver-specific knockout (L-AktDKO) or Control mice
respectively.

As

expected,

L-AktDKO

mice

were

glucose

intolerant

and

hyperinsulinemic, thus serving as a suitable genetic insulin resistant model (Figure
3.1A,B) (Lu et al., 2012). Consistent with previous work, these metabolic phenotypes are
normalized by simultaneous deletion of hepatic Foxo1 (L-AktFoxo1TKO) (Figure
3.1A,B) (Lu et al., 2012). To determine if deletion of liver FOXO1 alone was sufficient to
improve glucose tolerance during diet-induced insulin resistance, we injected 6-weeks
old Foxo1loxP/loxP mice with AAV-TBG-GFP or with AAV-TBG-CRE to induce liver-specific
deletion of FOXO1 (L-Foxo1KO) and placed them on a high-fat diet (60 kcal% fat;
D12492i, Research Diets) for 26 to 28 weeks after AAV injection to induce an obesity
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driven insulin-resistant phenotype. Under these conditions, mice with liver-specific
deletion of FOXO1 had improved glucose tolerance (Figure 3.1D) and lower circulating
insulin levels when compared to Control mice suggesting improved insulin sensitivity
(Figure 3.1E). This improvement in glucose tolerance was independent of weight loss
(data not shown) and consistent with previous data utilizing a different obesogenic diet
(Titchenell et al., 2015).
Given the extensive published literature, we focused on FGF21 as a potential
FOXO1-dependent hepatokine mediating the cell-nonautonomous control of insulin
sensitivity in following FOXO1 deletion. Our group recently reported that liver FOXO1
represses Fgf21 expression in the liver (Sostre-Colón et al., 2021), an observation
consistent with elevation of Fgf21 in FOXO1 deficient mouse models (Haeusler, Han and
Accili, 2010; Ling et al., 2017). In support of this notion, L-AktDKO mice displayed
decreased Fgf21 gene expression that was rescued completely in L-AktFoxo1TKO,
confirming the repressive effect of FOXO1 activity on Fgf21 expression (Figure 3.1C).
Similarly, liver-specific deletion of hepatic FOXO1 under diet-induced obesity conditions
increased hepatic Fgf21 gene expression compared to Control mice (Figure 3.1F). Our
group also reported recently that FOXO1 alone was sufficient to cause glucose
intolerance and fasting hyperinsulinemia, which correlated with decreased hepatic Fgf21
gene expression, consistent with the data presented in Figure 3.1 (Sostre-Colón et al.,
2021). Collectively, these data show that genetic inhibition of FOXO1 improves glucose
homeostasis in both genetic and dietary mouse models of insulin resistance. These
improvements in glucose homeostasis following FOXO1 deletion correlate with
increased hepatic Fgf21 gene expression in multiple models.
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Figure 3. 1: Hepatic AKT-FOXO1 axis regulates glucose tolerance, hyperinsulinemia and
Fgf21 expression
A) Glucose levels of Control, L-AktDKO, and L-AktFoxo1TKO mice housed at RT after i.p.
injection of 2 g/kg of glucose solution (n=15 for Control mice, n=9 for L-AktDKO mice, and n=8 for
L-AktFoxo1TKO mice). B) Fasting insulin levels of Control, L-AktDKO, and L-AktFoxo1TKO mice
housed at RT (n=11 for Control mice, n=7 for L-AktDKO mice, and n=8 for L-AktFoxo1TKO mice).
C) Relative mRNA levels of Fgf21 in liver from Control, L-AktDKO, and L-AktFoxo1TKO mice
housed at RT (n=13 for Control mice, n=9 for L-AktDKO mice, and n=11 for L-AktFoxo1TKO
mice). D) Glucose level of Control and L-Foxo1KO mice on HFD for 26-28 weeks after i.p.
injection of 2 g/kg of glucose solution (n=5 for Control HFD mice, and n=9 for L-Foxo1KO HFD
mice). E) Fasting insulin levels of Control and L-Foxo1KO mice on HFD for 26-28 weeks housed
at RT (n=5 for Control HFD mice, and n=9 for L-Foxo1KO HFD mice). F) Relative mRNA levels of
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Fgf21 in the liver from Control and L-Foxo1KO mice on HFD for 26-28 weeks housed at RT (n=9
for Control HFD mice, and n=7 for L-Foxo1KO HFD mice). Data are presented as means ±SEM.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Acute loss of hepatic FGF21 does not affect glucose or insulin tolerance in control or
mice lacking hepatic insulin signaling
To determine if the restoration of Fgf21 expression was required to improve
glucose homeostasis following AKT and FOXO1 deletion, we generated mice lacking
either FGF21 alone or mice lacking AKT1/2, FOXO1, and FGF21 (L-QKO) by injecting
AAV-TBG-CRE into Fgf21loxP/loxP or Akt1loxP/loxP, Akt2loxP/loxP, Foxo1loxP/loxP, Fgf21loxP/loxP
mice. In addition, AAV-TBG-GFP injected littermates mice served as Control. Successful
knockout of targeted genes was confirmed by measuring the expression of Akt2, Foxo1,
and Fgf21 in the liver and by measuring circulating levels of FGF21 of Control, LFgf21KO, or L-QKO (Figure 3.2A,B). First, we determined if acute loss of liver FGF21
alone impaired liver insulin signaling response to refeeding by monitoring AKT signaling.
Here, we performed fasting (16 hours) and refeeding (4 hours) experiments and
collected the liver for western blot analysis. We observed increased phosphorylation of
AKT2 in L-Fgf21KO mice after refeeding comparable to Control mice, suggesting normal
postprandial AKT activation in both control and L-Fgf21KO livers (Figure 3.2C). We also
observed a reduction in IGFBP1 expression upon refeeding similar to Control mice,
consistent with the typical decrease in FOXO1 activity upon refeeding (Figure 3.2C).
Finally, levels of hepatic glucokinase (GCK) were unaffected in L-Fgf21KO compared to
Control mice (Figure 3.2C). On the other hand, L-QKO mice showed the expected loss
of AKT signaling using the same feeding paradigm. In L-QKO mice, we observed a
decrease in phosphorylation of AKT2 upon refeeding and total AKT2 levels in both
fasted and refed conditions of L-QKO mice compared to Control mice (Figure 3.2D). In
addition, protein levels of IGFBP1 increased during fasting conditions but decreased
75

upon refeeding conditions of L-QKO mice (Figure 3.2D). Consistent with a mouse model
of deficient liver AKT signaling (Lu et al., 2012; Titchenell et al., 2016), L-QKO mice
showed a significant decrease in GCK protein levels both in fasting and refeeding
conditions (Figure 3.2D).
Next, we determined if liver-derived Fgf21 was required for glucose homeostasis
and asked if the normalization in glucose tolerance seen in L-AktFoxo1TKO mice is
dependent on the restoration of liver Fgf21 gene expression. Therefore, we first
measured glucose serum levels from mice fasted for 16 hours and/or refed for 4 hours.
No difference in fasting or refeeding glucose levels were observed between the three
genotypes (Figure 3.3A). Next, glucose tolerance test (GTT) and insulin tolerance test
(ITT) were performed, which did not reveal any significant abnormalities in glucose or
insulin tolerance in either liver-specific FGF21 knockout alone or L-QKO mice (Figure
3.3B,C). In support of the ITT assessment, fasted and/or ad libitum levels of circulating
insulin were no different between the genotypes (Figure 3.3D,E). These results indicate
that the acute deletion of liver FGF21 has minimal effects on glucose homeostasis under
normal conditions and does not contribute to the insulin-sensitizing effects of inhibition of
FOXO1 in AKT-deficient mice.
Although FOXO1 deletion corrects many glucose abnormalities of L-AktDKO
mice, it does not entirely restore the liver’s ability to store glycogen in the refed state,
confirming that AKT is required for postprandial glycogen deposition (Lu et al., 2012;
Titchenell et al., 2016). Consistent with this notion, L-QKO mice showed a significant
decrease in liver glycogen content compared to Control mice under refed conditions. In
contrast, no significant change is observed in L-Fgf21KO mice (Figure 3.3F), confirming
that liver AKT signaling is required for glycogen synthesis. This effect on glycogen
content paralleled the reduction in hepatic glucokinase expression observed in L-QKO
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mice (Figure 3.2C). Collectively, these data demonstrate that acute deletion of liverderived FGF21 has minimal effects on glucose homeostasis and insulin tolerance in
mice in vivo.
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Figure 3. 2: Acute loss of hepatic FGF21 alone does not affect liver insulin signaling
A) Relative mRNA levels of Akt2, Foxo1, and Fgf21 in the liver from Control, L-Fgf21KO, and LQKO mice housed at RT after 16 hours fast or 4 hours refed (n=4-9 per group/per condition). B)
FGF21 serum levels of Control, L-Fgf21KO and L-QKO mice after 16 hours fasting (n=8 for
Control mice, n=5 for L-Fgf21KO mice and n=6 for L-QKO mice). C) Western Blot analysis of
phosphorylation (p-) of AKT2 at Ser474, total AKT2, IGFBP1, and GCK of liver from Control and
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L-Fgf21KO mice housed at RT. D) Western Blot analysis of phosphorylation (p-) of AKT2 at
Ser474, total AKT2, IGFBP1, and GCK of liver from Control and L-QKO mice housed at RT. Data
are presented as means ±SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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Figure 3. 3: Acute loss of hepatic FGF21 does not affect glucose or insulin tolerance with
or without liver insulin signaling
A) Blood glucose level of Control, L-Fgf21KO, and L-QKO mice housed at RT after 16 hours fast
or 4 hours refed (n=5-9 per group/per condition). B) Glucose level of Control, L-Fgf21KO, and LQKO mice housed at RT after i.p. injection of 2 g/kg of glucose solution (n=20 for Control mice,
n=12 for L-Fgf21KO mice, and n=15 for L-QKO mice). C) Glucose level of Control, L-Fgf21KO,
and L-QKO mice housed at RT after i.p. injection of 0.75 U/kg of insulin (n=15 for Control mice,
n=8 for L-Fgf21KO mice, and n=13 for L-QKO mice). D) Insulin levels of Control, L-Fgf21KO, and
L-QKO mice housed at RT after 16 hours fasted (n=18 for Control mice, n=7 for L-Fgf21KO mice,
and n=15 for L-QKO mice). E) Insulin levels of random fed Control, L-Fgf21KO, and L-QKO mice
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housed at RT (n=13 for Control mice, n=7 for L-Fgf21KO mice, and n=9 for L-QKO mice). F) Liver
glycogen content of Control, L-Fgf21KO, and L-QKO mice housed at RT after 16 hours fast or 4
hours refed (n=4-9 per group/per condition). Data are presented as means ±SEM. *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001.

Loss of liver FGF21 does not affect adipose tissue insulin sensitivity or lipolysis in mice
with or without hepatic insulin signaling
As previously mentioned, FOXO1 deletion improves insulin sensitivity in LAktDKO mice in part via cell-nonautonomous control of adipocyte lipolysis in the white
adipose tissue (WAT) (Perry et al., 2015; Titchenell et al., 2016; Tao et al., 2018).
Therefore, we addressed if acute loss of liver FGF21 alone or the FOXO1-dependent
control over FGF21 affects insulin signaling and lipolysis in the adipose tissue. To
assess insulin signaling in white adipose tissue, we measured the phosphorylation and
activation status of AKT and the mTORC1 dependent target S6 after 16 hour-fasting or
after 4 hour-refeeding conditions in inguinal WAT (iWAT). Upon refeeding conditions, we
observed an increase in the phosphorylation of both AKT and S6 when compared to
fasted states in Control mice (Figure 3.4A). This increase upon refeeding was similar
between Control, L-Fgf21KO or L-QKO mice (Figure 3.4A). These data indicate that
loss of circulating FGF21 does not affect insulin signaling in white adipose tissue in vivo.
In addition to adipose tissue insulin signaling, we next probed the key lipolysis regulators
in epididymal WAT (eWAT) and iWAT. Here, we determined the phosphorylation status
of hormone-sensitive lipase (pSer660 HSL) and Perilipin (pSer522) in response to
fasting and refeeding (Duncan R.E., Ahmadian M, Jaworski K, Sarkadi-Nagy E, 2010;
Zechner et al., 2012; Dipilato et al., 2015; Manning and Toker, 2017). In all genotypes,
the phosphorylation status of HSL (pSer660) and Perilipin (pSer522) was increased
during fasting conditions and suppressed to a similar extent between all conditions
(Figure 3.4B,C). These effects on insulin and lipolysis signaling correlated with similar
suppression of circulating glycerol and free fatty acids in all genotypes (Figure 3.4D,E).
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Lastly, we performed ex vivo lipolysis assays in basal and in response to CL 316,243
treatment to stimulate lipolysis. Explants of eWAT from L-Fgf21KO, and L-QKO mice
induced glycerol levels to a similar extent as Control mice (Figure 3.4F). Taken together,
these data demonstrate that acute deletion of liver-derived FGF21 does not affect
adipose tissue lipolysis or insulin signaling in vivo.
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Figure 3. 4: Acute loss of hepatic FGF21 does not affect adipose tissue insulin signaling or
lipolysis in mice with or without liver insulin signaling
A) Western Blot analysis of phosphorylation (p-) of AKT1/2 at Ser474/474, Pan AKT,
phosphorylation (p-) of S6 at Ser240/244, S6, and HSP90 of iWAT from Control, L-Fgf21KO, and
L-QKO mice housed at RT after 16 hours fasted/ 4 hours refed. B) Western Blot analysis of
phosphorylation (p-) of HSL at Ser660, HSL, phosphorylation (p-) of Perilipin at Ser522, and
Perilipin of iWAT and eWAT from Control and L-Fgf21KO mice housed at RT after 16 hours
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fasted/ 4 hours refed. C) Western Blot analysis of phosphorylation (p-) of HSL at Ser660, HSL,
phosphorylation (p-) of Perilipin at Ser522, and Perilipin of iWAT and eWAT from Control and LQKO mice housed at RT after 16 hours fasted/ 4 hours refed. D) Glycerol serum levels of Control,
L-Fgf21KO, and L-QKO mice housed at RT after 16 hours fast or 4 hours refed (n=7-15 per
group/per condition). E) NEFA serum levels of Control, L-Fgf21KO, and L-QKO mice housed at
RT after 16 hours fast or 4 hours refed (n=7-15 per group/per condition). F) Glycerol levels of
Control, L-Fgf21KO, and L-QKO mice eWAT explants before and after 100 µM CL treatment (n=4
for Control mice and n=3 for L-Fgf21KO and L-QKO mice). Data are presented as means ±SEM.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Metabolic response to feeding upon acute loss of liver FGF21
In the liver, the AKT-FOXO1 axis serves as an important signaling node
downstream of insulin responsible for feeding-dependent regulation of gene expression
and metabolism (Lu et al., 2012). In addition to liver AKT-FOXO1 signaling in
fasting/refeeding regulation, FGF21 is suggested to affect genes involved in hepatic
glucose and lipid metabolism (BonDurant and Potthoff, 2018). Given that liver insulin
signaling via the AKT-FOXO1 axis and liver FGF21 are involved in the transcriptional
response to nutrient intake, we next determined how acute loss of hepatic FGF21
contributes to gluconeogenic and lipogenic gene expression in L-Fgf21KO and L-QKO
mice. G6pc and Pck1 levels in L-Fgf21KO and L-QKO mice were largely not different
from the Control mice during fasting; however, there was a partially blunting of G6pc and
Pck1 in L-QKO refed mice (Figure 3.5). Igfbp1 and Pgc1a expression of Control and LFgf21KO mice did not change during fasting; however, L-QKO mice partially increased
basal expression compared to Control mice. Upon refeeding, Igfbp1 and Pgc1a gene
suppression were normal in Control, L-QKO, and L-Fgf21KO mice (Figure 3.5). Irs2
showed no difference between the groups on both conditions (Figure 3.5). Lastly, the
lipogenic genes, Srebp1c and Gck were induced by refeeding in L-Fgf21KO mice while
L-QKO displayed a significant reduction in these lipogenic genes (Figure 3.5). These
results from the lipogenic genes (Gck, Srebp1c, and Fasn) in the L-QKO mice were
expected given that AKT-dependent activation of the mammalian target of rapamycin
84

complex 1 (mTORC1) is also required to drive postprandial lipogenic gene expression
(Titchenell et al., 2016).
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Figure 3. 5: Metabolic responsive genes to feeding in L-Fgf21KO and L-QKO mice
Relative mRNA levels of G6pc, Pck1, Igfbp1, Srebp1c, Fasn, Gck, Pgc1α, and Irs2 in liver from
Control, L-Fgf21KO, and L-QKO mice housed at RT after 16 hours fast or 4 hours refed (n=5-12
per group/per condition). Data are presented as means ±SEM. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
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DISCUSSION

In addition to liver-specific pathways to regulate systemic metabolism, liverderived circulating FGF21 affects carbohydrate and lipid metabolism (BonDurant and
Potthoff, 2018). Due to its positive effects on systemic glucose metabolism, several
pharmaceutical companies designed and tested FGF21 analogs and derivatives in
human clinical trials (Mu et al., 2012; Véniant et al., 2012; Kharitonenkov et al., 2013;
Kaufman et al., 2020). Unfortunately, efficacy was quite modest in terms of glycemic
control compared to rodent studies (Gaich et al., 2013; Talukdar, Zhou, et al., 2016;
Sanyal et al., 2018; Charles et al., 2019; Kaufman et al., 2020). Despite robust
pharmacological findings in rodents, there is a dearth of knowledge related to the
physiological role of FGF21 in systemic glycemic control, insulin sensitivity, and body
weight regulation. To address this knowledge gap, we used an acute loss-of-function
approach to determine the physiological role of hepatic FGF21 in both normal conditions
and the background of hepatic insulin signaling deficiency. Here, we show that acute
loss of hepatic FGF21 does not alter systemic glucose metabolism, insulin tolerance, or
adipose tissue lipolysis under either condition.
It is important to note that these results differ slightly from the two previously
published manuscripts investigating the role of liver-derived FGF21(Markan et al., 2014;
Stöhr et al., 2021). In Markan et al., mice with congenital liver-specific deletion of FGF21
have a very modest impairment in glucose tolerance under normal chow-fed conditions,
an effect that is more pronounced under-obesogenic conditions. Mechanistically, the
authors argue that brown adipose tissue (BAT) glucose uptake was impaired following
the loss of liver FGF21 under these conditions, suggesting that BAT response to FGF21
is required for proper systemic glucose uptake (Markan et al., 2014). There are two
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main differences between this study and ours: (1) as mentioned; this study was
performed in mice lacking liver FGF21 from birth, raising the possibility of other signaling
and compensatory metabolic mechanisms contributing to the metabolic phenotype, and
(2) the most significant phenotypes were observed under obesogenic conditions, which
were not explored in our manuscript. In our manuscript, we specifically decided to try
and minimize any compensation that can occur from a congenital loss-of-function;
therefore, we took advantage of the AAV-TBG system and developed an acute knockout
model of liver FGF21. Additionally, a major goal of our study was to define the
physiological role of FGF21 under non-obesogenic conditions to explore the biology of
FGF21 in controlling glucose homeostasis under normal conditions in vivo.
Similar to our manuscript, Stöhr et al. published that inhibition of hepatic insulin
action (induced by deletion of the insulin receptor substrate proteins) decreases hepatic
Fgf21 expression in a FOXO-1 dependent manner (Stöhr et al., 2021). The authors
employed adenoviruses to overexpress FGF21 and found it increased adipose tissue
glucose uptake that correlated with systemic insulin sensitivity changes. However, there
are some important technical differences between this study and the one described
here: (1) a congenital liver-specific Cre system was afforded the potential of
compensatory or secondary mechanisms to compensate (2) the use of adenoviruses to
overexpress FGF21 and short hairpin-expressing viruses to knock down hepatic Fgf21.
Here, we performed acute loss-of-function to minimize artifacts due to overexpression,
efficacy concerns of shRNA delivery to hepatocytes in vivo, and inflammation-induced by
adenovirus delivery in vivo that is known to induce acute bouts of hyperglycemia. Using
AAV methods to generate robust hepatocyte-specific knockouts in vivo, we did not
observe any change in glucose or insulin tolerance or adipose tissue insulin signaling

88

and lipolysis following acute knockout of FGF21 in either control mice or mice lacking
hepatic AKT and FOXO1 signaling under normal chow feeding conditions.
In addition to defining the physiological role of liver-derived FGF21 in animals
with intact hepatic insulin signaling, our data also showed that improvements in systemic
insulin sensitivity following FOXO1 deletion are unlikely to require intact FGF21. It is
important to note that these experiments do not question the robust insulin-sensitizing
effects of

pharmacological

FGF21 administration,

which are well-documented

(Kharitonenkov et al., 2005, 2007; Coskun et al., 2008; Xu, Lloyd, et al., 2009; Xu,
Stanislaus, et al., 2009; Gaich et al., 2013; Talukdar, Zhou, et al., 2016; BonDurant et
al., 2017; Murray et al., 2020).

Rather these studies were intended to clarify the

physiological role of hepatocyte-derived FGF21 on systemic metabolism using acute
genetic loss-of-function experiments in mouse models under non-obesogenic conditions.
Moreover, these experiments do not address the role of adipose tissue FGF21 signaling
in the acute insulin sensitizing effects of FGF21, which were explored in detail in
BonDurant et al 2017. Here, adipocyte specific deletion of the FGF21 obligate coreceptor, β-klotho, prevented the acute insulin sensitizing effect of FGF21 while also
indicating that insulin signaling in the adipocytes is required for the acute insulin
sensitizing effect of FGF21 (BonDurant et al., 2017). Moreover, this study does not
address how regulation of adipocyte lipolysis controls hepatic FGF21 production as
recently demonstrated by the Saltiel group. Here, the authors show that mice stimulated
with CL increased liver-derived FGF21 serum levels effect that was blunted when
treated with a lipolysis inhibitor (atglistatin) (Abu-Odeh et al., 2021).
In summary, hepatocyte-derived FGF21 is not required to maintain glucose
tolerance and insulin tolerance in mice under normal chow conditions. Furthermore,
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FOXO1-dependent control of FGF21 is not required for adipose tissue insulin sensitivity
and the subsequent cell-nonautonomous control of hepatic insulin sensitivity.
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CHAPTER 4: Discussion and Future Directions
SUMMARY
My thesis work sought to evaluate how hepatic insulin signaling, specifically via
the transcription factor FOXO1, controls adipose tissue biology. The motivation for these
studies is to provide fundamental knowledge on the inter-tissue communication system
that mobilizes energy for systemic homeostasis and heat production as well as glucose
and insulin tolerance. Several studies started to delineate the mechanisms of how interorgan communication is critical for the acute response to cold exposure (Schreiber et al.,
2017a; Shin et al., 2017a; Simcox et al., 2017a; Heine et al., 2018c; Ameka et al., 2019).
However, major gaps remain in our understanding of how other metabolic organs
generate energy sources to activate and fuel BAT thermogenesis. In Chapter 2, we
demonstrated a role for hepatic insulin action in response to acute cold exposure and
the cell-nonautonomous regulation of adipose tissue lipolysis and thermogenesis.
Mechanistically, we show that liver insulin signaling via the AKT-FOXO1 axis
orchestrates the systemic thermogenic response to acute cold by regulating
catecholamine-induced lipolysis in the WAT and inducing BAT thermogenesis via
FGF21-dependent and independent mechanisms (Figure 4.1).

These studies

highlighted novel pathways of inter-organ communication between the liver and adipose
tissue in metabolic regulation.
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Figure 4. 1: Schematic of the working model for Chapter 2

In complementary studies, Chapter 3, we sought to determine how hepatic
insulin signaling contributes to the regulation of endogenous hepatic FGF21 expression
and its physiological role as a FOXO1-dependent hepatokine in the regulation of
metabolism. To address this, we used acute loss-of-function experiments to determine
the physiological role of hepatic FGF21 in both normal conditions and in the background
of hepatic insulin signaling deficiency. We concluded that liver-derived FGF21 is not
required to maintain glucose tolerance or insulin tolerance in mice under normal chow
conditions. Furthermore, FOXO1-dependent control of FGF21 is not required for adipose
tissue insulin sensitivity and the subsequent cell-nonautonomous control of hepatic
insulin sensitivity (Figure 4.2).
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Figure 4. 2: Schematic of the working model for Chapter 3

Taken together, these two studies have developed a deeper understanding on
the cell-autonomous and cell-nonautonomous regulation of liver hepatic insulin signaling
via FOXO1. FOXO1 cell-autonomous regulation of FGF21 expression is required for
proper SNA in the BAT (Ameka et al., 2019) and thermogenesis upon acute cold
exposure. However, it is dispensable for the FOXO1-dependent cell-nonautonomous
control of adipose tissue insulin sensitivity or lipolysis and the subsequent control of
glucose tolerance or insulin tolerance. In addition, we demonstrated that hepatic FOXO1
cell-nonautonomously regulates adipose tissue lipolysis by a circulating factor, however
this circulating factor remains unknown and future studies should address it.
FUTURE DIRECTIONS
Understanding the role of hepatic FOXO1 in the regulation of the thermogenic gene
program and adipose tissue lipolysis
Human studies demonstrate that BAT thermogenesis after cold training is
associated with increased oxidative capacity, insulin sensitivity, and decreased body fat
mass (Yoneshiro et al., 2013; Blondin et al., 2014; Lee et al., 2014). Therefore, the
ability of the BAT to increase energy expenditure has made it a potential target for
combating obesity and associated diseases (Seale and Lazar, 2009), and identification
of factors that regulate the thermogenic gene program and activity is of great
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importance. We have demonstrated that hepatic FOXO1 regulates BAT thermogenic
gene expression and protein levels of UCP1 and thermogenic function. One of our main
conclusions is that FOXO1 cell-nonautonomously regulates WAT lipolysis to supply
enough energy substrate to the BAT to fuel the thermogenic response. However,
bypassing the deficiency in energy substrate by providing food to mice that lack AKT in
the liver (and have increased FOXO1 activity) restores cold tolerance, independent of
increasing UCP1 protein levels. These results suggest that inhibition of liver FOXO1 is
required for proper UCP1 protein levels, and if the system is overridden with ample
energy substrates, minimal levels of UCP1 are sufficient to increase the thermogenic
response. Nevertheless, understanding the mechanistic relationship of how liver FOXO1
regulates UCP1 transcriptionally and translationally is of great interest.
Here we mechanistically tested the role of direct insulin signaling in the adipose
tissue using mice that lack the main AKT isoform in the fat, AKT2, as well as the role of
liver-derived FGF21 in mediating the transcriptional induction of UCP1 in BAT. However,
we demonstrate that neither of these pathways mediate this response. Therefore, further
studies in vivo and ex vivo should address this. Based on the UCP1 literature, several
transcriptional pathways are involved in the regulation of BAT thermogenic activation in
response to adrenergic stimulus such as the p38 MAPK signaling. p38 activates Ucp1
transcription by phosphorylating the activating transcription factor 2 (ATF2) and
peroxisome proliferator-activated receptor gamma coactivator (PGC1α) (Cao et al.,
2004). In addition to p38, other transcription factors that increase thermogenic gene
expression are estrogen related receptors (ERR), ZFP516, IRF4 and CREB (Kong et al.,
2014; Emmett et al., 2017; Ahmadian et al., 2018; Brown et al., 2018). Taking advantage
of the ample literature on UCP1 regulation we can first try to identify whether any of
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these players are responsible for mediating liver FOXO1 regulation of UCP1. In addition,
given that this is a cell-nonautonomous regulation measuring serum metabolites or
performing proteomic analysis could provide a series of possible candidates that
mediate this effect. Together, these experiments could provide novel insight into how
liver FOXO1 regulates UCP1 transcription.
As mentioned before, one of our main conclusions is that hepatic FOXO1
controls adipose tissue thermogenesis by regulating lipolysis in the WAT. We
demonstrated that this defect in adipose tissue lipolysis is not due to a defect in the
adipose tissue per se, but rather by an unknown circulating factor. We mechanistically
explored if this unknown circulating factor was the hepatokine FGF21, however, we
observed that loss of liver FGF21, upon cold exposure, does not decrease WAT
lipolysis. Therefore, determining this unknown liver FOXO1-dependent circulating factor
is of great importance. Two well-known pathways that inhibit adipocyte lipolysis are
signaling via insulin and adenosine receptors (Johansson et al., 2008; Choi et al., 2010).
Both insulin and adenosine inhibit lipolysis by decreasing cAMP levels, which leads to a
decrease in the cAMP/PKA signaling pathway (Kitamura et al., 1999; Braun et al., 2018).
Previous studies demonstrate that loss of hepatic AKT causes hyperinsulinemia and
increased liver adenosine, and that hepatic deletion of FOXO1 results in the
normalization of both (Lu et al., 2012). However, Titchenell et al. demonstrated that
insulin is unable to inhibit WAT lipolysis in mice lacking liver AKT (Titchenell et al.,
2016). Therefore, we conclude that insulin is unlikely the reason for decreased lipolysis
in mice that lack hepatic AKT. Thus, to determine if adenosine is decreasing WAT
lipolysis, performing in vivo and ex vivo lipolysis experiments in the presence or absence
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of an adenosine receptor antagonist will help determine if increased adenosine is the
mechanism by which liver FOXO1 affects WAT lipolysis.
On the other hand, previous studies suggest that increased inflammation leads to
the activation of phosphodiesterase 3B (PDE3B) by the protein kinases IKKε and TBK1,
causing catecholamine resistance and a decrease in WAT lipolysis (Mowers et al.,
2013). We demonstrated that loss of hepatic AKT increases IL1- in WAT, and this is
rescued upon concomitant deletion of hepatic FOXO1. Therefore, increased
inflammation may contribute to the anti-lipolysis effects. Experiments investigating the
activation of PDE3B by IKKε and TBK1 in mice that lack AKT in the liver would provide
useful information to determine this hypothesis. Using a similar approach as mentioned
before with in vivo and ex vivo strategies in the presence or absence of an IKKε/TBK1
inhibitor, amlexanox, and determining its effect in WAT lipolysis will help determine if
liver FOXO1-dependent increases in inflammation is the cause of the decrease in WAT
lipolysis. Nevertheless, there is also the possibility that neither adenosine nor increased
inflammation drives the reduced induction of lipolysis in mice lacking hepatic AKT. If this
is the case, performing liquid chromatography coupled with tandem mass spectrometry
on mouse serum would enable us to identify and quantify other lipolysis-regulating
factors in circulation.
We started to delineate the mechanism of the impairment observed in adipose
tissue lipolysis in our mouse model lacking hepatic AKT. We observed that
phosphorylation of PKA-dependent substrates was decreased in the WAT of mice
lacking liver AKT when exposed to acute cold exposure or upon a β3-selective agonist,
CL (data not shown), these data suggest a reduction in cAMP levels. Therefore, given
the mechanism of how both adenosine and PDE3B works, they are both strong
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candidates as the potential circulating factor regulating this decrease in adipose tissue
lipolysis.
Determine the acute role of an FGF21 analogue on insulin sensitivity and NASH
pathology
Identification of insulin sensitizers is of great importance due to the prevalent
observed increase in cases of T2DM. T2DM is known to be strongly correlated with
other metabolic diseases, such as obesity and non-alcoholic fatty liver disease (NAFLD).
The latter being the most common form of liver disease worldwide and is divided into
benign fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) (Younossi et al.,
2015). Although reducing a patient’s weight, either by lifestyle changes or bariatric
surgery are two proven ways to treat and improve NASH, there are presently no FDA
approved medical treatments for NASH (Promrat et al., 2010; Vilar-Gomez et al., 2015).
Therefore, there is a desperate need to discover new potential therapeutic targets that
will help improve and treat hepatic steatosis and NASH. FGF21 has emerged as a
potential therapeutic treatment for obesity and T2DM due to its insulin-sensitizing and
weight reduction effects seen in obese and insulin-resistant mice and non-human
primates (Kharitonenkov et al., 2005, 2007; Coskun et al., 2008; Xu, Lloyd, et al., 2009;
Gaich et al., 2013a). Unfortunately, efficacy was modest as an anti-diabetes, anti-obesity
treatment in human clinical trials (Gaich et al., 2013b; Talukdar et al., 2016; Sanyal et
al., 2018; Charles et al., 2019; Kaufman et al., 2020). However, recent pre-clinical and
clinical data indicate that FGF21 analogues may improve NAFLD hallmarks such as
steatosis and fibrosis independently of weight loss (Tillman and Rolph, 2020; Yang, Xu
and Kharitonenkov, 2022).
Here we demonstrate that endogenous FGF21 is not required for glucose and
insulin tolerance as well as that it is not required for proper WAT insulin sensitivity and
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lipolysis. However, this conclusion does not argue against the robust insulin-sensitizing
effects

of

pharmacological

FGF21

administration,

which

is

well-established

(Kharitonenkov et al., 2005, 2007; Coskun et al., 2008; Xu, Lloyd, et al., 2009; Xu,
Stanislaus, et al., 2009; Gaich et al., 2013b; Talukdar et al., 2016; BonDurant et al.,
2017; Murray et al., 2020). Therefore, we conclude that the main role of FGF21 as an
insulin sensitizer is under a pharmacological effect and that understanding the
mechanism of how acute action of a clinically validated FGF21 analog, improves insulin
sensitivity and NAFLD/NASH, via a weight-independent manner would have great
translational implications. In vivo experiments using several mouse models of defective
insulin sensitivity or mice under NASH-inducing diets would provide mechanistic insight
on how an FGF21 analog can acutely improve both pathologies in a weight independent
manner. Studies to determine the correct dose must be performed, as well as follow up
experiments on glucose and insulin levels to address the insulin sensitivity question and
measuring markers of inflammation and fibrosis to determine any improvement in NASH.
These studies will provide a more fundamental understanding on the mechanism and
efficacy of clinically approved FGF21 analogs as a treatment for insulin sensitivity but
more importantly for NASH pathology.
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Table 5. 1: key resources table

REAGENT or RESOURCE

SOURCE

IDENTIFIER

UCP1

R&D Systems

Cat#MAB6158;
RRID:AB_105724
90

HSP90

Cell Signaling
Technology

Cat# 4874;
RRID:AB_212121
4

AKT1

Cell Signaling
Technology

Cat# 2938;
RRID:AB_915788

AKT2

Cell Signaling
Technology

Cat# 2964;
RRID:AB_331162

HSL

Cell Signaling
Technology

Cat# 4107;
RRID:AB_229690
0

P-HSL (Ser660)

Cell Signaling
Technology

Cat# 4126;
RRID:AB_490997

Perilipin

Cell Signaling
Technology

Cat# 9349;
RRID:AB_108299
11

P-Perilipin (Ser522)

Vala Sciences

Cat# NC0859674

Santa Cruz

Cat# sc-6000;
RRID:AB_212308
7

Antibodies

IGFBP1
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P-PKA Substrate

Cell Signaling
Technology

Cat# 9624;
RRID:AB_331817

P-AKT1/2 (Ser473/Ser474)

Cell Signaling
Technology

Cat# 4060;
RRID:AB_231504
9

P-AKT2 (Ser474)

Cell Signaling
Technology

Cat# 8599;
RRID:AB_263034
78

S6

Cell Signaling
Technology

Cat# 2217;
RRID:AB_331355

P-S6 (Ser240/244)

Cell Signaling
Technology

Cat# 2215;
RRID:AB_331682

P-PRAS40 (Thr246)

Cell Signaling
Technology

Cat# 2997;
RRID:AB_225811
0

Bacterial and virus strains
AAV8-TBG-CRE

University of
Pennsylvania
Vector Core

N/A

AAV8-TBG-eGFP

University of
Pennsylvania
Vector Core

N/A

Murine Liver

This Paper

N/A

Murine Brown Adipose Tissue

This Paper

N/A

Murine White Inguinal Adipose Tissue

This Paper

N/A

Murine Epididymal Adipose Tissue

This Paper

N/A

Biological samples

Chemicals, peptides, and recombinant proteins
CL 316,243

Sigma-Aldrich

C5976

Norepinephrine

Sigma-Aldrich

A9512

FluoroBrite DMEM

Thermo Fisher
Scientific

A1896701

Roche

04693159001

Sigma-Aldrich

P5726-5ML

Protease Inhibitor Cocktail Tablets
Phosphatase Inhibitor Cocktail 2
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Phosphatase Inhibitor Cocktail 3

Sigma-Aldrich

P0044-5ML

M-MuLV

New England
Biolabs

M0253L

SYBR Green

Fisher Scientific

4368702

Glycerol

MP Biomedicals

800688

10% Buffered Formalin

Fisher Scientific

SF100-4

TRIzol

Fisher Scientific

10-296-028

Critical commercial assays
Free Glycerol Reagent

Sigma-Aldrich

F6428

Infinity Triglyceride Reagent

Thermo Scientific

TR22421

NEFA-HR (2) Reagent A

Wako Chemicals

999-34691

NEFA-HR (2) Reagent B

Wako Chemicals

991-34891

NEFA-HR (2) Solvent A

Wako Chemicals

995-34791

NEFA-HR (2) Solvent B

Wako Chemicals

993-35191

Insulin ELISA

Crystal Chem

90080

FGF21 ELISA

BioVendor

RD291108200R

RNeasy Mini Kit

Qiagen

74106

RNase-Free DNase Set

Qiagen

79254

Experimental models: cell lines
Murine primary hepatocytes

This Paper

N/A

Experimental models: organisms/strains
Mouse/B6: Akt1loxp/loxp; Akt2loxp/loxp

Lu et al., 2012

N/A

Mouse/B6: Akt1loxp/loxp; Akt2loxp/loxp; Foxo1loxp/loxp

Lu et al., 2012

N/A

Ouyang et al., 2012

N/A

This Paper

N/A

(Leavens et al.,
2009)

N/A

Mouse/B6: FoxoAAA1loxp/loxp
Mouse/B6: Akt1loxp/loxp; Akt2loxp/loxp; Foxo1loxp/loxp;
Fgf21loxp/loxp
Mouse/B6: Akt2loxp/loxp
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Mouse/B6: AdipoqCre

Jackson
Laboratories

Stock No: 028020

This Paper

N/A

Oligonucleotides
See Table 2 for RT PCR primers

Software and algorithms
Prism V8.4.2

QuantStudio Software V1.4.2—for QuantStudio
5 Real-Time PCR Systems

GraphPad

https://www.graph
pad.com/scientific
-software/prism/

Thermo Fisher

https://www.therm
ofisher.com/order/
catalog/product/A
28140?SID=srchhjA28140#/A28140
?SID=srch-hjA28140

Table 5. 2: List of real-time PCR Primers listed 5’ to 3’

Gene

Forward

Reverse

Ucp1

TCAGGATTGGCCTCTACGAC

TGCCACACCTCCAGTCATTA

Dio2

AATTATGCCTCGGAGAAGACCG

GGCAGTTGCCTAGTGAAAGGT

Fgf21 GCTGCTGGAGGACGGTTACA

CACAGGTCCCCAGGATGTTG

Akt2

ATGGATTACAAGTGTGGCTCCC
C

GTGCCTGGTATTCTGCAGAACC

Foxo
1

CTGGGTGTCAGGCTAAGAGT

GGGGTGAAGGGCATCTTT

Fasn

GCTGCGGAAACTTCAGGAAAT

AGAGACGTGTCACTCCTGGACTT

Acc

TGACAGACTGATCGCAGAGAAA
G

TGGAGAGCCCCACACACA

Scd1

CCGGAGACCCCTTAGATCGA

TAGCCTGTAAAAGATTTCTGCAAA

Igfbp
1

GGAGATCGCCGACCTCAAG

CTGCAGCTAATCTCTCTAGCACTT
TATAG

Gck

CCCTGAGTGGCTTACAGTTC

ACGGATGTGAGTGTTGAAGC
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Gk

CCCAAGAGAAGGATGGGTAGAA
CA

GGTCAAGCCACACCACGGCATTA
T

Gpd1

TTCACTGCGGTGTACAAAGTGT
GC

CATTCACATGTGTTCCGGGTGGT
T

Gpd2

GAAGGGGACTATTCTTGTGGGT

GGATGTCAAATTCGGGTGTGT

Klb

GATGAAGAATTTCCTAAACCAG
GTT

AACCAAACACGCGGATTTC

Adrb
1

GAAAGCAGGTGAATGCAAAGC

CCGAACCTCAGAGAGAAAGGA

Adrb
2

TTGCAGTGGATCGCTATGTTG

CGATAGCTTTCTTGTGGGTGG

Adrb
3

TCGACATGTTCCTCCACCAA

GATGGTCCAAGATGGTGCTT

IL-1b

TGGAGAGTGTGGATCCCAAGCA
AT

TGTCCTGACCACTGTTGTTTCCCA

Mcp1

TCACCTGCTGCTACTCATTCACC
A

TACAGCTTCTTTGGGACACCTGC
T

Tnfa

TCTCATGCACCACCATCAAGGA
CT

TGACCACTCTCCCTTTGCAGAAC
T

F4/80 TCAAATGGATCCAGAAGGCTCC
CA

TGCACTGCTTGGCATTGCTGTAT
C

EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All mice used in all experiments were on a C57/B6J background and were males. To
generate Akt1loxp/loxp; Akt2loxp/loxp; Foxo1loxp/loxp; Fgf21loxp/loxp we crossed Akt1loxp/loxp;
Akt2loxp/loxp; Foxo1loxp/loxp mice with Fgf21loxp/loxp (kind gift from Dr. Soccio, UPenn).
Akt1loxp/loxp; Akt2loxp/loxp, Akt1loxp/loxp; Akt2loxp/loxp; Foxo1loxp/loxp, Foxo1AAAloxp/loxp mice (kind
gift Ming Li, Sloan Kettering) and Akt1loxp/loxp; Akt2loxp/loxp; Foxo1loxp/loxp; Fgf21loxp/loxp were
injected at 6-14 weeks of age with 1011 genomic copies of adeno-associated virus 8
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expressing either GFP or Cre recombinase under the liver-specific promoter, thyroxinebinding globulin (TBG), per mouse to generate Control, L-AktDKO, L-AktFoxo1TKO, LFoxo1AAA, and L-AktFoxo1Fgf21QKO mice (Lu et al., 2012; Ouyang et al., 2012b). The
Control group consisted of GFP-injected littermates floxed for each group. Experiments
were

performed

2-weeks

post

AAV8-injection.

AdipoqCre-positive

male

mice

heterozygous for Akt2loxp/loxp were bred to females homozygous for Akt2loxp/loxp (Leavens
et al., 2009), to generate AdipoqCre-positive experimental mice homozygous for
Akt2loxp/loxp (F-AKT2KO) and AdipoqCre-negative male mice homozygous for Akt2loxp/loxp
that served as Controls that were used at the ages of 8-14 weeks for experiment. All
mice were housed at RT (22C) unless specified otherwise. Animal use followed all
standard and guidelines of the Institutional Animal Care and Use Committee (IACUC) at
the University of Pennsylvania.
Primary Hepatocyte Isolation
Hepatocytes were isolated from 8-14 weeks random fed mice 2-weeks post AAV8injection using a two-step collagenase/DNAse digestion protocol (Titchenell et al., 2015)
and plated in M199 media containing 5mM glucose, 10% FBS, 500nM dexamethasone,
1% Pen/Strep, and 100 nM insulin. Following attachment, cells were changed to M199
media containing 5mM glucose, 500nM dexamethasone. Cells were lysed in RIPA buffer
described below and subjected to western blot analysis.
METHOD DETAILS
Cold Tolerance Test
Mice were transferred from room temperature to single houses at 4°C. Rectal
temperature were measured every hour and mice were sacrificed after a 10-degree
dropout of initial temperature or up to 5 hours at 4°C.
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Body Temperature
Core body temperature was measured in mice using a rectal probe (Type T
Thermocouple Meter; 91428-02).
Thermogenic Capacity and Energy Expenditure
For thermogenic capacity measurement, CLAMS metabolic chambers (Columbus
Instruments) were warmed to 25C. Mice were placed in chambers and sedated with 75
mg/kg Pentobarbital. After 3 rounds of reading, mice were injected with 1 mg/kg NE
intra-peritoneally and VO2 was measured until mice woke up. For basal energy
expenditure, mice were placed into CLAMS metabolic chambers warmed to 25C.
Oxygen consumption and carbon dioxide production were calculated as ml/hr. For NE
response, oxygen consumption was normalized to initial Control mice response (T0’).
Food Intake
Cumulative food intake was determined by manually weighing the food from single
cages every six days.
Lipolysis In Vivo upon CL 316,243 injection
Ad-libitum fed mice were sedated with 75 mg/kg Pentobarbital. After, mice were injected
with 1mg/kg of CL 316,243 intra-peritoneally. Retro-orbital blood collection took place
before and 30 min after CL injection, to measured FFA serum levels.
Lipolysis Ex Vivo
Fresh eWAT depots were dissected from ad-libitum fed mice and put into FluoroBrite
DMEM. The depots were then cut into 4-6 small similar-sized pieces and transferred into
150 µL FluoroBrite DMEM supplemented with 2% FA-free BSA in 96-well plates for 30
min for pre-incubation. To analyze basal lipolysis, tissues were transferred into 150 µL of
fresh FluoroBrite DMEM supplemented with 2% FA-free BSA for 60 min. Then, the
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tissues were transferred and pre-incubated for 30 min in 150 µL FluoroBrite DMEM
supplemented with 2% FA-free BSA in the presence of 100 µM CL 316,243. To analyze
stimulated lipolysis, tissues were transferred into 150 µL fresh FluoroBrite DMEM
supplemented with 2% FA-free BSA and 100 µM of CL 316,243 for another 60 min.
Glycerol content was analyzed by combining 5 µL of supernatant and 200 µL of Free
Glycerol Reagent and incubating for 15 min at room temperature before measuring
absorbance at 540 nm. At the end of the experiment, the tissue pieces were delipidated
by CHCL3 extraction and solubilized in 0.3 N NaOH/0.1% SDS at 65°C overnight.
Protein content was determined using Pierce BCA Protein assay. Results are expressed
as µmol of glycerol per mg of tissue protein.
Body Composition Analysis
Body weight and body composition were measured using EchoMRI™ 3-in-1 system
nuclear magnetic resonance spectrometer (Echo Medical Systems).
Western Blotting
Adipose tissue samples were homogenized in RIPA (50mM Tris HCl, 1% Triton x100,
0.5% Sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM EDTA) buffer
supplemented with protease inhibitor cocktail tablets, and phosphatase inhibitor cocktail
II and III in a TissueLyser (Qiagen). Samples were separated on 4-15% Mini-PROTEAN
TGX pre-cast gels. Primary antibodies used were UCP1, HSP90, AKT1, AKT2, HSL, PHSL, Perilipin, P-Perilipin, IGFBP1, P-PKA Substrate, P-AKT1/2, P-AKT2, S6, P-S6, and
P-PRAS40.
mRNA Isolation and Real-Time PCR
Total RNA was isolated from the frozen livers and adipose tissue samples using the
RNeasy Plus kit from Qiagen. Complementary DNA was generated using M-MuLV
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reverse transcriptase and quantitated for the relative expression of genes of interest by
real time PCR using the SYBR Green dye-based assay.
Glucose Tolerance Test
For glucose tolerance test, overnight fasted mice were injected with 2 g/kg of glucose
solution intra-peritoneally. Blood glucose was measured at 0, 15, 30, 60, 120 min after
glucose injection.
Glycerol Tolerance Test
For glycerol tolerance test, 8 hours fasted mice were injected with 2 mg/kg of glycerol
solution intra-peritoneally. Glycerol levels were measured at 0, 30, 60, 90, 120, 150, 180
min after glycerol injection.
Histology
BAT was fixed in 10% buffered formalin overnight, dehydrated in ethanol, paraffinembedded and sectioned. Sections were stained with hematoxylin and eosin. Scale bar,
100 µm or 200 µm as indicated.
Hepatic Triglyceride
Liver samples were homogenized in cell lysis buffer (140mM NaCl, 50mM pH7.4 Tris,
250 µL 20% Triton-X) the samples were then solubilized with 20 µl of 1% deoxycholate
and incubated at 37 °C for 10 min. For triglyceride measurements, 200 µl of infinity
triglyceride reagent was added and incubated for 10 min at 37 °C. The triglyceride
content was determined using a standard curve generated with triglyceride standard.
Serum Collection and Extraction for Acylcarnitine Levels
Blood was collected after a fasting cold tolerance test in a 1.5mL EDTA-free tube, after
30 min at RT the samples were centrifuge at 8000 rpm for 5 min at RT. Then, ice-cold
methanol was added to the sample and kept at RT for 20 min, before centrifuge at 4°C
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for 10 min. The supernatant was transfer to a new tube and the pellet was mix with
40:40:20 ratio of methanol:acetonitrile:water solution and kept on ice for 10 min before
centrifuge at 4°C for 10 min. The supernatant was combined with the previous one to
make a final extract. Finally, the extract was dried and sent for MS analysis by the Penn
Metabolomics Core at Princeton University as previously described (Papazyan et al.,
2016).
Blood Chemistry
Serum FFA concentration was measured using NEFA-HR (2) R1 and R2 reagents
following manufacture’s instruction, glycerol concentrations were measured using 5 µL of
sample and 200 µL free glycerol reagent. Both methods were quantified using enzymatic
colorimetric analysis. Blood glucose levels were measured using a glucometer. Insulin
levels were measured using an ultrasensitive ELISA. FGF21 levels were measured
using an ELISA.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using One-way ANOVAs when more than two groups
were compared, Two-way ANOVAs when two conditions were analyzed, and unpaired
two-tailed Students’ t test when two groups were being assayed. All data were presented
as mean ±SEM. * indicates p-value <0.05, ** indicates p-value <0.01, *** indicates pvalue <0.001.
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Corresponding to Chapter 3: Acute deletion of the FOXO1-dependent hepatokine
FGF21 does not alter basal glucose homeostasis or lipolysis in mice
Adapted from: Sostre-Colón J, Gavin MJ, Santoleri D, Titchenell PM. Acute deletion of the
FOXO1-dependent hepatokine FGF21 does not alter basal glucose homeostasis or lipolysis in
mice. Endocrinology. 2022 Mar 18: bqac035. doi: 10.1210/endocr/bqac035. Epub ahead of print.
PMID: 35303074.

EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Akt1loxp/loxp, Akt2loxp/loxp; Akt1loxp/loxp, Akt2loxp/loxp, Foxo1loxp/loxp; Akt1loxp/loxp, Akt2loxp/loxp,
Foxo1loxp/loxp, Fgf21loxp/loxp;

Fgf21loxp/loxp and Foxo1loxp/loxp male mice (Lu et al., 2012;

Titchenell et al., 2015; Sostre-Colón et al., 2021) were injected at 6-14 weeks of age with
1011 genomic copies of adeno-associated virus expressing either GFP or Cre
recombinase under the liver-specific promoter, thyroxine-binding globulin (TBG), per
mouse to generate Control, L-AktDKO, L-AktFoxo1TKO, L-QKO, L-Fgf21KO, and LFoxo1KO mice. The Control group consisted of GFP-injected littermates floxed for each
group. Experiments in non-obesogenic diets were performed 2-3 weeks post AAV
injection. All mice were housed at RT (22C). To induce diet-induced obesity, Control
and L-Foxo1KO mice were put under a high-fat diet (60 kcal% fat; D12492i, Research
Diets) after AAV injection for 26-28 weeks. For fasted/refed experiments, mice were
fasted for 16 hours for the fasted conditions and then placed under ad libitum fed
conditions for 4 hours to complete the 4 hours refed condition. Animal use followed all
standards and guidelines of the Institutional Animal Care and Use Committee (IACUC)
at the University of Pennsylvania.
Western Blotting
Liver and adipose tissue samples were homogenized in RIPA (50mM Tris HCl, 1%
Triton x100, 0.5% Sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM EDTA) buffer
supplemented with protease inhibitor cocktail tablets (Roche; 04693159001), and
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phosphatase inhibitor cocktail II and III (Sigma-Aldrich; P5726; P0044) in a TissueLyser
(Qiagen). Samples were separated on 4-15% Mini-PROTEAN TGX pre-cast gels
(BioRad; 4561084). Primary antibodies used were HSP90 (1:1,000; Cat# 4874;
RRID:AB_2121214), AKT2 (1:1,000; Cat# 2964; RRID:AB_331162), P-AKT2 (1:1,000;
Cat# 8599; RRID:AB_26303478), IGFBP1 (1:1,000; Cat# sc-6000; RRID:AB_2123087),
GCK (gift from Dr. Magnuson). P-AKT1/2 (1:1,000; Cat# 4060; RRID:AB_2315049), AKT
(1:1,000; Cat# 4691, RRID:AB_915783), P-S6 (1:1,000; Cat# 2215; RRID:AB_331682),
S6

(1:1,000;

Cat#

2217;

RRID:AB_331355),

P-HSL

(1:1,000;

Cat#

4126;

RRID:AB_490997), HSL (1:1,000; Cat# 4107; RRID:AB_2296900), P-Perilipin (1:5,000;
Cat# 4856; RRID:AB_2909466), Perilipin (1:1,000; Cat# 9349; RRID:AB_10829911).
mRNA Isolation and Real-Time PCR
Total RNA was isolated from the frozen livers samples using the RNeasy Plus kit from
Qiagen. Complementary DNA was generated using M-MuLV (New England Biolabs;
M0253L) reverse transcriptase and quantitated for the relative expression of genes of
interest by real-time PCR using the SYBR Green (Fisher Scientific; 4368702) dye-based
assay.
Glucose Tolerance Test (GTT)
For the glucose tolerance test, overnight fasted mice were injected with 2 g/kg of
glucose solution intra-peritoneally. Blood glucose was measured at 0, 15, 30, 60, 120
min after glucose injection.
Insulin Tolerance Test (ITT)
For the insulin tolerance test, 5 hours fasted mice were injected with 0.75 U/kg of insulin
intra-peritoneally. Blood glucose was measured at 0, 15, 30, 45, 60 min after insulin
injection.
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Blood Chemistry
Serum FFA concentrations were measured using NEFA-HR (2) R1 and R2 reagents
(Wako Chemicals; 999-34691; 991-34891) following manufacture’s instruction, and
glycerol concentrations were measured using 5 µL of sample and 200 µL free glycerol
reagent (Sigma-Aldrich; F6428). Both methods were quantified using enzymatic
colorimetric analysis. Insulin levels were measured using an ultrasensitive ELISA
(Crystal Chem; 90080; RRID:AB_2783626). FGF21 levels were measured using an
ELISA (BioVendor; RD291108200R; RRID:AB_2909467).
Hepatic Glycogen Content
Liver samples were homogenized in 6% perchloric acid solution. Then, the samples
were centrifuged at 4oC at 16,200g for 10 min. Next, the supernatant was diluted and
centrifuged again at the same conditions. After this, 10N KOH was added to the sample
to reduce it to a 6-7 pH level. Next, the samples were centrifuged at the same conditions
one last time, and the supernatant was saved. Finally, 100 µL amyloglucosidase (1
mg/mL stock solution) was added to 20 µL of the sample and incubated at 40oC for 2
hours while shaking. The Glucose Assay Reagent (Sigma; G3293) was used to
determine the glycogen content.
Lipolysis Ex Vivo
Fresh eWAT depots were dissected from ad-libitum fed mice and put into FluoroBrite
DMEM (Thermo Fisher Scientific; A1896701). The depots were then cut into 5 small
similar-sized pieces and transferred into 150 µL FluoroBrite DMEM supplemented with
2% FA-free BSA in 96-well plates for 30 min for basal pre-incubation. To analyze basal
lipolysis, tissues were transferred into 150 µL of fresh FluoroBrite DMEM supplemented
with 2% FA-free BSA for 60 min. This media was collected to measure glycerol levels of
basal lipolysis. Then, to analyze CL 316,243 -stimulated lipolysis, the tissues were
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transferred and pre-incubated for 30 min in 150 µL FluoroBrite DMEM supplemented
with 2% FA-free BSA in the presence of 100 µM CL 316,243 (Sigma-Aldrich; C59765MG). To analyze stimulated lipolysis, tissues were transferred into 150 µL fresh
FluoroBrite DMEM supplemented with 2% FA-free BSA and 100 µM of CL 316,243 for
another 60 min. This media was collected to measure glycerol levels of the stimulated
lipolysis. Glycerol levels were analyzed by combining 5 µL of supernatant and 200 µL of
Free Glycerol Reagent (Sigma-Aldrich; F6428) and incubating for 15 min at room
temperature before measuring absorbance at 540 nm. At the end of the experiment, the
tissue pieces were delipidated by CHCL3 extraction and solubilized in 0.3 N NaOH/0.1%
SDS at 65°C overnight. Protein content was determined using Pierce BCA Protein
assay. Results are expressed as µmol of glycerol per mg of tissue protein.
Quantification And Statistical Analysis

Statistical analysis was performed using One-way ANOVAs when more than two groups
were compared, Two-way ANOVAs when two conditions were analyzed, and unpaired
two-tailed Students’ t-test when two groups were being assayed. All data were
presented as ±SEM. * indicates p-value <0.05, ** indicates p-value <0.01, *** indicates
p-value <0.001, **** indicates p<0.0001.
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